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Abstract 
 
Background and Aims. Interleukin (IL)-17 is now known to be involved 
in a number of chronic inflammatory disorders. However, the 
mechanisms regulating its production in inflammatory bowel disease 
(IBD) are still unclear. Methods. Endoscopic biopsies or surgical 
specimens were taken from inflamed and uninflamed colonic mucosa of 
72 IBD patients (38 with Crohn’s disease and 34 with ulcerative colitis), 
and normal colon of 38 control subjects. IL-17 and interferon (IFN)- 
were detected by ELISA in the supernatants of biopsies cultured ex vivo, 
and anti-CD3/CD28-stimulated lamina propria mononuclear cells 
(LPMCs) incubated with IL-12, IL-23, IL-1β plus IL-6, transforming 
growth factor (TGF)-β1, or anti-IL-21 neutralising antibody. Intracellular 
flow cytometry was performed to analyse mucosal Th17 and Th1/Th17 
cells. Results. IL-17 production by organ culture biopsies was higher in 
IBD inflamed mucosa than IBD uninflamed mucosa and controls, and 
was equivalent in amount to IFN-. Anti-CD3/CD28-stimulated IBD 
LPMCs produced higher IL-17 amounts compared to controls. The 
percentages of Th17 and Th1/Th17 cells were increased in IBD patients 
than controls. IL-23 and IL-1 plus IL-6 had no effect on IBD LPMC 
production of IL-17, however IL-12 markedly increased IFN- 
production and decreased IL-17 production. TGF-β1 dose-dependently 
decreased IFN-, but had no significant inhibitory effect on IL-17 
production. Blocking IL-21 significantly down-regulated IL-17 
production. Conclusions. Our findings support a role for IL-12, TGF- 
and IL-21 in modulating IL-17/IFN- production in IBD. The abundant 
IL-17 in inflamed IBD mucosa may help explain the relative lack of 
efficacy of anti-IFN- antibodies in clinical trials of Crohn’s disease. 
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Abbreviations 
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OCTN  Organic cation transporters 
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PBS  Phosphate buffered saline 
PMA  Phorbol 12-myristate 13-acetate 
RNA  Ribonucleic acid 
ROR  Retinoic acid receptor-related orphan receptor  
RPMI  Roswell park memorial institute 
STAT  Signal transducer and activator of transcription 
T-bet  T-box transcription factor expressed in T cells 
TCR  T cell receptor 
TGF  Transforming growth factor 
Th1   T helper cell type 1 
TLR  Toll-like receptor 
TNBS  Trinitrobenzene sulfonic acid 
TNF   Tumour necrosis factor 
Treg  Regulatory T cells 
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Introduction 
 
1. Inflammatory Bowel Disease 
 
1.1 Definition 
 
Crohn’s disease (CD) and ulcerative colitis (UC) represent the two main 
forms of inflammatory bowel disease (IBD), an idiopathic relapsing 
chronic disorder characterized by a swinging course. While CD is a 
transmural chronic inflammation potentially affecting any 
gastrointestinal tract from mouth to anus, UC is a non-transmural disease 
affecting the colon with a caudo-cranial extension without patchiness or 
skip lesions [1]. Table 1 summarizes clinical and pathological features 
which help differentiating between CD and UC.  
 
Table 1. Clinical and pathological features for differential diagnosis 
between Crohn’s disease and ulcerative colitis. 
 
 Crohn’s disease Ulcerative colitis 
Clinical features   
   Abdominal pain Severe, mainly in right  
lower quadrant 
Cramping, mainly in 
left lower quadrant 
 
   Diarrhoea  Frequent  
 
Frequent  
   Hematochezia In 20-30% of patients, in 
distal colonic disease 
 
Always in active 
disease 
   Abdominal mass Right lower quadrant 
(inflamed or stenotic 
ileum) 
Left lower quadrant 
in inflamed sigma or 
slim patients 
 
   Malnutrition Frequent Uncommon 
 
   Abdominal distension Uncommon 
 
In severe disease 
only 
 
   Obstructive symptoms  Frequent No 
 
   Perianal disease/fistulas Up to 30% of patients No 
 
   p-ANCA + (Crohn’s colitis) ++ (+++ in sclerosing 
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cholangitis)  
 
   ASCA ++ +/- 
 
Complications   
   Abscess More frequent perianal  
than intra-abdominal 
 
Rare 
   Toxic megacolon No Rare 
 
   Stenosis Common Rare 
 
   Colorectal cancer Rare, most frequent in  
colonic disease 
Relative risk related 
to disease duration, 
extension and activity 
 
Extraintestinal 
manifestations 
  
   Erythema nodosum Uncommon Rare 
 
   Pyoderma gangrenosum Very rare Rare 
 
   Sclerosing cholangitis Rare Uncommon (5-15%) 
 
   Arthralgia/arthritis Very frequent  Frequent 
 
Endoscopic aspects   
   Distribution Any segment of the 
gastrointestinal tract 
 
Continuous from the 
rectum 
   Ileal involvement Frequent Rare (backwash 
ileitis) 
 
   Rectal involvement 30-50% Almost always 
 
     Continuous disease Not frequent Always 
 
   Linear and serpinguous 
ulcers 
 
Frequent No 
 
   Ileal cobblestone 
appearance 
 
Frequent No 
 
   Skip lesions  
 
Frequent No 
   Stenosis Uncommon Rare, always 
suspicious for 
carcinoma 
 
   Mucosal edema Uncommon Frequent 
 
   Ulcers Deep Often superficial and 
extensive 
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       Circumferential   
inflammation 
 
Rare Frequent 
Histological features   
   Goblet cell mucin 
depletion 
 
No Frequent 
 
   Crypt architectural 
distortion  
 
No Frequent 
   Crypt abscesses Rare Frequent 
 
   Granulomas Uncommon No 
 
   Submucosal 
inflammation 
 
Very frequent Rare 
 
Radiological aspects   
   Intestinal wall 
thickening 
 
Extensive Moderate 
 
   Mesenteric  
adenomegalies 
 
Frequent Not frequent 
 
       Mesenteric fat wrapping 
 
Frequent No 
  
ASCA, Anti-saccharomyces cerevisiae antibodies; p-ANCA, Anti-neutrophil 
cytoplasmatic antibodies (perinuclear pattern); +/-, association variably seen; 
+, associated; ++, frequently associated; +++, strongly associated. 
 
 
 
1.2 Epidemiology 
 
The frequency of IBD is much higher in Northern Europe, United 
Kingdom, and North America, where incidence rates begin now to 
stabilize after a progressive increase in the last 50 years (5-6 cases per 
100.000 persons/year with a prevalence of 27-106/100.000 for CD, and 
6-15 cases per 100.000 persons/year with a prevalence of 80-
150/100.000 for UC). On the contrary, incidence and prevalence rates are 
continuously increasing in low-incidence regions, such as Southern 
Europe, Asia and developing countries [2,3]. The risk of IBD is related 
to ethnic and racial factors, as shown by the higher prevalence of CD and 
UC in North American Ashkenazi Jews [4-6]. However, relevant 
epidemiological differences between Jewish people living in Israel and 
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those living elsewhere suggest that environmental factors and lifestyle 
must be involved [7,8]. CD is slightly more frequent in females (M:F = 
1:1.2) and occurs earlier (mean age 26) than UC (M:F = 1.2:1; mean age 
34). Another pick of incidence is between 60s and 80s, more frequently 
for CD than UC [9,10]. 
 
1.3 Clinical Features of Inflammatory Bowel Disease 
 
Crohn’s disease 
Typical features of CD are the common localization in the terminal 
ileum, the discontinuous involvement of the gastrointestinal tract, and the 
development of complications such as abscesses, strictures and fistulas. 
In CD, inflammation involves all layers of gut wall (mucosa, submucosa, 
muscolar layer and sierosa) and tends to extend to mesenteric fat and 
lymph nodes. In early stages lesions typically include cryptic abscess and 
aphthous ulcers. The chronicization of inflammation leads to the onset of 
non-caseating granulomas which, although representing a 
pathognomonic feature of CD, are present in less than 50% of 
endoscopic biopsies [11] and in 70% of surgical specimens [12], since 
they localize more often in the submucosa than in the mucosa. Other 
common features are lymphoid aggregates in the submucosa, abundant 
lympho-monocytic infiltrate in the lamina propria and mucosal 
fissurations, which eventually become real penetrating fistulas through 
the gut wall. These microscopic alterations correspond to a series of 
macroscopic lesions such as aphthous ulcers which converge and 
surround areas of unaffected mucosa giving the gut mucosa the typical 
“cobblestone” appearance. Possible complications of CD are (i) intra-
abdominal or intraparietal perianal abscesses, (ii) fistulas, linking gut 
with another intestinal tract, a contiguous organ (e.g. bladder, ureter, 
vagina) or the skin, expecially at site of surgical scars, in the peri-
umbelical or peri-anal areas, and (iii) strictures, determined by the 
progressive fibrosis of the intestinal wall. 
Patients affected by CD present with variable symptoms depending on 
site, phenotype and severity of inflammation and the presence of 
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complications. Typical symptoms are diarrhea, abdominal pain, much 
more frequent and persistent in comparison to UC, and weight loss. 
Additional symptoms are asthenia, anorexia, nausea, vomiting and fever, 
while extraintestinal manifestations (affecting joints, skin, eye, ecc.) are 
present in at least 1/4 of patients with CD. 
According to the Vienna classification [13], CD may be classified in 
three main clinical phenotypes: fistulising (or penetrating), stricturing, 
and non-penetrating/non-stricturing (or luminal). Even though disease 
location is usually stable, the behavior tends to change over time [14]. At 
diagnosis 70% of patients have a luminal disease, but after 25 years of 
follow-up very few patients have an uncomplicated disease, and virtually 
all of them have developed either stricturing or penetrating disease. 
Moreover, after 20 years of disease more than 2/3 of patients have 
undergone surgical resection of intestinal strictures [15]. Unlike UC, life 
expectancy in CD is slightly reduced [16]. 
 
Ulcerative colitis 
UC is a relapsing mucosal inflammatory bowel disease affecting the 
colon with a caudo-cranial extension. Macroscopically, the colon is 
freckled with superficial ulcers, caused by abnormal matrix 
metalloproteinase activation with subsequent enterocyte apoptosis [17]. 
This continuous damage-regeneration process that occurs in inflamed 
areas, leads to the growth of pseudopolyps, which are a common feature 
in UC. Histologically, UC appears with microscopic abscesses at the 
base of the crypts of Lieberkühn, crypt architectural distortion and 
branching, Paneth cell metaplasia, mucin depletion and lamina propria 
cell infiltration (especially by neutrophils, eosinophils, plasmacells and 
macrophages).  
UC can be divided into proctitis (rectal involvement only), left-sided 
colitis (involving the sigmoid colon with or without involvement of the 
descending colon), or pancolitis (global colonic involvement). Patients 
with pancolitis can also present inflammation of the terminal ileum, 
called “backwash ileitis”. In the natural history of UC, disease extent 
tends to change: more than half of patients with left-sided colitis will 
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progress proximally, while in more than 2/3 of patients with pancolitis 
the extent of colonic involvement will decrease [18]. Unlike CD, patients 
with UC have a normal life expectancy [19]. 
Clinical features are typically bloody diarrhoea, abdominal cramping and 
rectal tenesmus. Symptoms are less severe in proctitis and left-sided 
colitis than pancolitis. Extraintestinal manifestations of UC are similar to 
CD, even if incidence is different. Sclerosing cholangitis, a chronic 
cholestatic liver disease, characterized by fibrosing inflammatory 
destruction of the intrahepatic and extrahepatic bile ducts, occurs in 
about 3% of UC patients [20]. Toxic megacolon and colorectal cancer 
are the most important complications of UC. Toxic megacolon is a rare 
and life-threatening complication, characterized by signs and symptoms 
of peritoneal involvement, occurring in severe and diffuse UC; 
fortunately its incidence is decreasing, thanks to a better control of the 
disease by new biological therapies. The prevalence of colorectal cancer 
in patients with UC is approximately 3.7% overall, and 5.4% for patients 
with pancolitis. The cumulative probability of colon cancer development 
is estimated of 2%, 8% and 18% respectively after 10, 20 and 30 years of 
disease duration [21,22]. Risk factors for colorectal cancer include extent 
and duration of UC, presence of backwash ileitis, coexisting primary 
sclerosing cholangitis, a family history of sporadic colorectal cancer and 
young age at diagnosis [22]. In the last 10 years the prevalence of 
colorectal cancer in UC patients is decreasing, thanks to surveillance 
colonoscopy and advancements in treatment, both chemotherapic and 
surgical.  
 
1.4 Diagnosis 
 
The diagnosis of IBD is made on the base of endoscopic, radiologic, 
histological and blood tests together with the evaluation of clinical 
conditions and the degree of disease activity [23]. Four steps need to be 
followed in the diagnosis of IBD: (i) differentiate IBD from other type of 
colitis and between CD and UC (Table 1); (ii) identify the clinical 
phenotype in case of CD or evaluate the extent of disease in case of UC, 
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since therapies can be different; (iii) modulate the therapeutic decision on 
the base of disease activity; (iv) indentify complications that need 
particular treatments or can be worsen by others.  
Ileocolonoscopy with multiple biopsies is fundamental for the diagnosis 
of IBD. In CD the macroscopic aspect of mucosa is characterized by 
deep aphthous or longitudinal, polygonal ulcers which alternate with 
unaffected areas conferring the typical aspect of cobblestone to gut 
mucosa, especially of terminal ileum. Discontinuity of lesions and spared 
rectum often make it possible to differentiate CD from UC. 
Macroscopically, the degree of inflammation can be evaluated on the 
base of mucosal erythema, bleeding (spontaneous or after the passage of 
the colonscope), and the presence of ulcers and inflammatory 
pseudopolyps, the last ones being more common in UC. Microscopically, 
the presence of granulomas, normality of goblet cells and abundant 
infiltrate of T lymphocytes and macrophages in the lamina propria, may 
help making CD diagnosis, while crypt abscesses, crypt architectural 
distortion with mucin depletion, Paneth cell metaplasia and lamina 
propria cell infiltrate are typical features of UC. 
A standard plain X-ray is useful in patients with severe or fulminant UC 
to evaluate the degree of intestinal distension, especially in toxic 
megacolon. Conventional double-contrast barium enema has been largely 
replaced by colonoscopy, and its role is limited to patients with colonic 
stenosis. Ultrasound, computed tomography and magnetic resonance 
imaging (MRI) cannot substitute full colonoscopy, even if their 
importance in IBD imaging has increased, providing essential 
information for diagnosis, management, follow-up and detection of 
potential complications [24]. Radiolabeled leukocyte scan with 
99m
Tc and 
Positron Emission Tomography are reliable and non-invasive techniques 
in monitoring response to therapy [25,26]. 
 
1.5 Therapy 
 
The primary end points of active IBD therapy are: (i) induction of 
remission; (ii) maintenance of remission; (iii) management of 
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complications. 
 
Crohn’s disease 
Therapeutic strategies are different on the base of the site of intestinal 
lesions (ileo-caecal or colonic disease), the presence of complications 
(fistula, strictures) and the severity of the disease. 
Induction of remission. Patients with mild to moderate colonic CD can 
be treated with budesonide or 5-aminosalicylic acid (5-ASA) orally. 
Patients who do not respond to mesalazine or budesonide, or with a 
moderate to severe disease should be treated with systemic 
corticosteroids. Only 50% of these patients achieve prolonged remission, 
while the other half requires further strategies. In case of cortico-
dependence or -resistance a more aggressive treatment with 
immunoppressors (azathioprine, 6-mercaptopurine or methotrexate) or 
biological therapies (monoclonal antibodies) should be considered. The 
evidence of an association between infliximab, a chimeric murine-human 
monoclonal antibody, and acute infusion reactions, loss of efficacy, and 
delayed hypersensitivity reactions [27] has led to the development of less 
immunogenic, humanized, or fully human antibodies against tumor 
necrosis factor (TNF)-α, like adalimumab [28]. In USA a third anti-TNF 
antibody, a pegylated humanized Fab’ fragment called certolizumab 
pegol, has been approved for CD [29,30]. The involvement of different 
cytokines in the pathogenesis of CD has led to the development of new 
selective biological therapies which are currently used in phase II and III 
trials. Among them etanercept (a fully human dimeric fusion protein) 
[31], onercept (a recombinant form of the human soluble p55 TNF 
receptor binding protein) [32], and CDP571 (a humanized IgG1 
monoclonal antibody to TNF) [33] have failed to induce and maintain 
remission in patients with CD. Fontolizumab (a humanized anti-
interferon (IFN)- antibody) also failed to reach the primary end point in 
phase II trials but had some efficacy at higher doses [34]. A promising 
strategy is the blocking of interleukin (IL)-12/23, which acts at the 
beginning of the Th1 pro-inflammatory cascade. The IL-12/23 p40 
subunit is targeted by two human monoclonal antibodies, ABT-874 [35] 
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and CNTO-1275 ustekinumab [36], both effective in the induction of 
response in moderate to severe CD in phase II trials. While the blockade 
of T-cell activation has not shown any efficacy in previous trials [37], 
ongoing studies are evaluating the safety and efficacy of monoclonal 
antibodies against IL-6, IL-10, and IL-17, which are involved in the 
pathogenesis of CD at different levels. Selective adhesion molecule 
inhibitors, such as natalizumab (a recombinant humanized IgG4 
monoclonal antibody to α4-integrin) block adhesion and subsequent 
leukocyte migration into the gut [38]. Because of the onset of progressive 
multifocal leukoencephalopathy in patients treated with natalizumab 
[39], this drug has not been approved for CD in Europe, and a phase III 
trial with a more selective anti-α4β7-integrin antibody (vedolizumab) has 
been started.  
Maintenance of remission. It is achieved mainly with 
immunosuppressors or with biological therapies; the last ones in 
particular allow steroid sparing and favour mucosal healing in patients 
with active CD during treatment with immunosuppressors.  
Management of fistulizing CD. Antibiotic therapy with cyprofloxacin or 
metronidazole is the first choice in perianal disease, even though there is 
no evidence of a sure efficacy of this strategy. As a second-line 
treatment, azathioprine and 6-mercaptopurine can be considered. Patients 
with draining fistula, despite treatment with antibiotics and 
immunosuppressors, can benefit from the association between infliximab 
or adalimumab (after having excluded the presence of abscesses with an 
MRI scan) and seton sutures of chronic fistula [40]. 
Surgery. In CD, unlike UC, surgery is not curative. Generally, it is 
indicated when fibrotic strictures causing an intestinal occlusion or 
fistula complicated by abdominal abscesses occur. Since recurrences 
after surgery are quite common, recent studies suggest a possible role for 
infliximab in combination with azathioprine in preventing them [41]. 
 
Ulcerative colitis 
Induction of remission. First-line therapy for patients with mild to 
moderate UC is 5-ASA, given orally or by topical formulations 
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depending on lesion distribution [42]. Patients who do not respond to 
mesalazine [43] should be treated with systemic corticosteroids [44] that 
still remain the foundation for inducing remission in UC. Patients with 
severe active UC, without signs of systemic infection, who fail to 
respond to oral prednisone need intravenous corticosteroids. If 
intravenous steroid therapy fails, other therapeutic options should be 
considered, such as immunosuppressors including cyclosporine [45,46] 
or tacrolimus [46]. Also infliximab has shown a significant benefit in 
achieving clinical response and remission [47,48]. Open-labeled clinical 
trials have shown that adalimumab is well-tolerated and appears to be 
effective in maintaining clinical remission in patients with UC, including 
those who have previously lost their response to or cannot tolerate 
infliximab [49,50]. As in CD, vedolizumab showed a higher efficacy 
than placebo for the induction of clinical and endoscopic remission in 
patients with active UC [51]. 
Maintenance of remission. First-line therapy for maintenance of 
remission is oral mesalazine and analogues [52,53]. In addition rectal 
mesalazine can be used in patients with proctitis or procto-sigmoiditis. 
Prolonged administration of mesalazine reduces the risk of colorectal 
cancer, reinducing enterocyte apoptosis [54]. Patients who relapse during 
maintenance therapy with mesalazine, those who are steroid-dependent, 
or those who have obtained clinical remission only with cyclosporine or 
tacrolimus, can be effectively treated with azathioprine and 6-
mercaptopurine [52], or infliximab which can be considered a good 
steroid-sparing drug in maintaining remission [47,48]. 
Surgery. Unlike CD, surgery can be curative in patients with UC. 
Emergency surgery is indicated in complicated patients (perforation, 
refractory rectal bleeding, and toxic megacolon not responsive to medical 
management) [55]. Elective surgery is indicated in patients with 
dysplasia or frank carcinoma, severe UC refractory to medical 
management, or when long-term therapies with immunosuppressors or 
infliximab are contraindicated [56,57]. 
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1.6 Aetiopatogenesis 
 
The etiology of IBD is still unknown, but it is clearly the result of a 
combination of environmental, genetic and immunological factors 
(Figure 1) [58].  
 
 
 
Figure 1. Genetic, immunologic and environmental factors involved in 
the etiopathogenesis of chronic inflammatory bowel diseases. CARD15, 
caspase activation recruitment domain family-15; CD, Crohn’s disease; 
NOD-2, nucleotide-binding-oligomerisation domain-2; NSAIDs, non-
steroideal anti-inflammatory drugs; OCTN, organic cationic 
transporter; UC, ulcerative colitis. 
 
Genetic factors 
Familiarity. Genetic studies have shown that in monozygotic twins the 
concordance rate for CD ranges from 20% to 50%, whereas in dizygotic 
twins brought up in the same environment is less than 10% [59,60]. The 
concordance rate of UC is about 16% in monozygotic twins and 4% in 
dizygotic twins [61]. CD and UC patients have a first-degree relative 
affected by IBD in 5-22% and 6-16% of cases, respectively [62]. 
NOD2/CARD15 gene. Among the CD susceptibility loci identified by 
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genome-wide scan, NOD2 (nucleotide-binding-oligomerization domain-
2), which is localized on chromosome 16 in the IBD1 locus, has been the 
most extensively studied [63-67]. It codifies CARD15 (caspase 
activation recruitment domain family-15), an intracellular protein 
expressed in the lamina propria by macrophages, neutrophils, dendritic 
cells, and Paneth cells, which plays a key role in intestinal innate 
immunity. CARD15 recognizes muramyl dipeptide, a component of both 
Gram-positive and Gram-negative bacteria, thus inducing the production 
of pro-inflammatory cytokines which are involved in determining 
intestinal inflammation. In CD patients NOD2 mutations are associated 
with an earlier onset of the disease, ileal localization, and presence of 
extensive strictures and entero-enteric fistulas. 
Other genes. Multiple genes are associated with both CD and UC, 
including IBD5 locus localized on chromosome 5, where genes codify 
for a family of organic cation transporters, namely OCTN1 and OCTN2 
[68], and IBD3 locus on chromosome 6 containing genes which codify 
for the major histocompatibility complex [66]. In particular, the HLA-
DRB*0103 aplotype is associated with a more severe form of UC, while 
most of the IBD-related extraintestinal manifestations are associated with 
HLA-B27 or HLA-B35 (arthropaties), or with HLA-B44 or HLA-
DRB*0103 (uveitis) [69]. 
 
Immunological factors 
It is commonly accepted that IBD is a consequence of an inappropriate 
mucosal immune response to the gut flora (Table 2). 
 
Table 2. Mechanisms of altered innate immune response determining 
loss of oral tolerance to commensal luminal bacteria in chronic 
inflammatory bowel diseases. 
 
Mechanism Cells involved Effect 
Reduced mucin 
production 
Goblet cells Reduced protective 
effect of the 
epithelial glicocalix  
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Reduced secretory 
immunoglobulin A 
production 
 
Plasmacells Increased 
susceptibility to 
bacterial infections 
Reduced defensin 
production 
 
Paneth cells expressing 
altered NOD2 proteins in 
patients with CARD15 
gene mutation 
 
Malfunction of 
antimicrobial 
activity of 
defensins 
Abnormal expression of 
toll-like receptors 
 
Epithelial cells Loss of control of 
epithelial cells-
bacteria 
interactions 
 
Abnormal activation and 
maturation of non-
tolerogenic dendritic 
cells 
Mucosal dendritic cells 
(antigen presenting cells 
with a crucial role in 
detecting and sampling 
luminal antigens) 
 
Polarization of T 
lymphocytes to an 
inflammatory 
phenotype (Th1, 
Th17) 
 
CARD15, caspase activation recruitment domain family-15; NOD2, nucleotide-
binding-oligomerisation domain-2; Th, T helper. 
 
Although the exact immunological mechanisms have not been 
completely clarified, the co-presence of multiple factors seems to be 
responsible for the activation of an inflammatory cascade which 
ultimately leads to the intestinal lesions (Figure 2). 
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Figure 2. Schematic representation of inflammatory bowel disease 
immunopathogenesis. The disruption of the epithelial barrier, 
determined by a loosening of intercellular junctions, is responsible for 
the paracellular transmigration of bacterial antigens (1). Bacteria can 
also trigger an inflammatory process by direct interaction with epithelial 
cells through Toll-like receptors (TLR) (15), or because they are 
captured by dendritic cells which can open tight junctions and extend 
their pseudopodes across the epithelium (10). Dendritic cells, which 
have lost their tolerogenic properties, polarize naïve T lymphocytes in T 
helper cell type (Th)1, via activation of the intracellular transcription 
factor T-bet, or in Th17, via interleukin (IL)-23 (11), or in Th2 via IL-4 
(14). In Crohn’s disease, bacterial antigens are aberrantly presented by 
macrophages to naïve T cells, which polarize in Th1 cells and start 
secreting huge amount of pro-inflammatory cytokines. Among them, 
interferon (IFN)- promotes the macrophage production of IL-12, which 
in turn sustains the activation of T cells (4). A defective lamina propria 
lymphocyte apoptosis (3) is responsible for the increased survival of T 
cells. On the contrary, ulcerative colitis is dominated by Th2 cytokines, 
such as IL-5 and IL-13, mainly produced by natural killer T cells 
infiltrating the lamina propria. In both Crohn’s disease and ulcerative 
colitis, IL-17, produced by Th17 lymphocytes, promotes the recruitment 
of neutrophils into the inflamed gut (13). Also IL-8, secreted by epithelial 
cells stimulated by IL-17 (12), or for a direct interaction of epithelial 
TLR (15) with lumen bacteria, promotes the recruitment of neutrophils 
from the inflamed mucosa. Crohn’s disease and ulcerative colitis share 
crucial end-stage pathways, characterized by the release of high 
amounts of tumour necrosis factor (TNF)-α from activated macrophages, 
which promotes the recruitment of neutrophils into the inflamed gut by 
the up-regulation of adhesion molecules on the vascular endothelium of 
mucosal blood vessels, which interact with integrines expressed on T 
lymphocytes (9). TNF-α is also responsible for the epithelial damage, 
determining the mucosal disepithelization and ulceration (5), and 
promotes the fibroblast production of matrix metalloproteinases (MMPs) 
which are directly responsible for connective tissue degradation and 
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ulceration. In Crohn’s disease, TNF-α also leads to the formation of 
granulomas (8), unbalances fibroblastic secretion toward an excess of 
metalloproteinase tissue inhibitors (TIMP) with collagen deposition, 
fibrosis and strictures (7), o di MMP with the onset of fistulas (6).  
 
Epithelial barrier defect. A genetically-determined defect in intestinal 
permeability has been reported in IBD patients and in 10-30% of healthy 
first-degree relatives of CD patients carrying NOD2 mutations 
[64,70,71]. In particular, a leaking epithelium is the likely factor 
responsible for the paracellular passage of bacterial antigens, which, 
once in the lamina propria, are aberrantly presented by macrophages to T 
cells which become activated. Furthermore, bacteria can trigger an 
inflammatory process even if they do not pass through the intestinal 
barrier, either because they are captured by dendritic cells which extend 
their pseudopodes through the intercellular spaces, or via Toll-like 
receptors expressed on epithelial cells [72] (Figure 2).  
Defect of lymphocyte apoptosis. A defective lamina propria lymphocyte 
apoptosis due to an imbalance between pro- and anti-apoptotic genes is 
supposed to be responsible for the increased survival of T cells, which 
release higher amount of pro-inflammatory cytokines thus perpetuating 
the gut mucosal damage [73] (Figure 2). 
Increased production of cytokines. In CD both dendritic cells, which 
have lost their tolerogenic properties, and activated macrophages 
polarize naïve T lymphocytes in T helper cell type (Th)1 cells [72]. The 
Th1 cytokine IFN-γ promotes the macrophage production of IL-12 which 
in turn sustains the activation of T cells [74] (Figure 2). On the contrary, 
UC is supposed to be dominated by Th2 cytokines, such as IL-5 and IL-
13 [74,75]. Higher levels of IL-17, a pro-inflammatory cytokine 
produced by a newly described lymphocyte population, namely Th17, 
have been found both in CD and UC [76]. IL-17 might contribute to the 
pathogenesis of IBD by promoting the recruitment of neutrophils into the 
inflamed gut through the induction of IL-8 secretion by epithelial cells 
[77]. Nonetheless, CD and UC share crucial end-stage pathways, as 
shown by the enhanced production in both conditions of IL-21 [78], IL-
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23 [79], and TNF-α which perpetuates the mucosal damage [80] (Figure 
2). 
 
Environmental factors 
Diet. There is no evidence for the role of food in IBD pathogenesis, 
although it has been hypothesized that an excessive intake of refined 
sugar or polyunsaturated fats can increase the risk of IBD, in particular 
CD [81]. 
Smoke. Cigarette smoke worsens the course of CD, favours fistula and 
stricture formation, and increases the number of flares and post-surgical 
relapses. Recently, also passive smoke has been identified as a risk factor 
for CD [82]. Conversely, in UC smoke seems to be protective, and it 
correlates to a less frequent flare of the disease.  
Infectious agents. Due to its resemblance to John’s disease, a chronic 
granulomatous gastroenteritis of ruminants, CD has been thought to be 
associated with infection by Mycobacterium avium subspecies 
paratuberculosis [83,84]. Although Mycobacterium avium 
paratuberculosis has been identified in tissue and blood of CD patients 
[85], anti-tubercular therapy was not effective in this condition [86]. The 
demonstration that mice kept in sterile conditions do not develop colitis 
strongly supports the hypothesis that also normal gut flora can be 
involved in the pathogenesis of IBD. In particular, research has focused 
on Bacteroides [87] and Escherichia coli [88] which produce adhesion 
molecules able to promote intestinal epithelial colonization and 
cytotoxins that are responsible for epithelium disruption and 
inflammatory responses. There is very poor evidence about the role of 
viruses and, up to now, there is no evidence that vaccination with live 
attenuated vaccines of measles, mumps or rubella viruses can cause IBD 
[89]. 
Drugs. There is some evidence supporting an association between non-
steroidal anti-inflammatory drug use and flares of IBD [90]. A recent 
meta-analysis has provided evidence of an association between the use of 
oral contraceptive agents and development of IBD, in particular CD [91]. 
Stress. The possible role of psychological stress and depression in 
25 
 
inducing flares in patients with quiescent disease is quite controversial, 
although recent evidence shows close interaction between nervous and 
immune system [92]. 
Appendicectomy. Epidemiological studies suggest that appendicectomy 
is protective against UC [93]. Conversely, it is associated with a higher 
risk of developing intestinal strictures in CD [94]. 
 
 
2. Animal Models of Inflammatory Bowel Disease and 
the Recent Advances in Genetics 
 
2.1 Traditional murine models of CD 
 
Several animal models of intestinal inflammation have been developed 
using chemical induction, immune cell transfer, or genetic 
manipulations. The majority of animal models exhibit Th1-dominant 
immune responses, and they have been used widely for studying CD. 
Although CD affects both small (ileitis) and large (colitis) intestines, 
only some CD models develop inflammation in the small intestine. In 
contrast to Th1-mediated models, mouse models developing Th2-
mediated colitis for the study of UC are limited. Animal models cannot 
fully reflect human diseases, but they have provided important 
opportunities to examine the mechanisms of IBD more closely. Indeed, 
during the last decade animal models have not only contributed to our 
understanding of the mechanisms of IBD but also provided useful 
interventions for developing novel therapeutic strategies [95].  
Chemically induced models. This group of animal models requires 
administration of an exogenous chemical agent for the induction of 
colitis. Examples include the trinitrobenzene sulfonic acid (TNBS) [96], 
dextran sodium sulfate (DSS) [97], and oxazolone [98]. Chemically 
induced models are useful for studying biochemical pathways of 
inflammation or for performing antigen-specific studies, such as in the 
case of hapten-induced gut inflammation (TNBS). These models are also 
26 
 
useful in providing proof of concept for therapeutic interventions in a 
simple and relatively inexpensive way. In addition, these models are 
particularly valuable in the dissection of specific aspects or events on the 
overall background of intestinal inflammation. For example, DSS-
induced colitis is characterized by epithelial disruption resulting in 
luminal bacterial translocation and subsequent infiltration of neutrophils 
and other acute immune cells. However, although these events might be 
important in initiating gut inflammation, DSS colitis can be generated in 
the absence of lymphocytes [99], and does not represent the chronic 
phases of disease. Therefore, DSS colitis can be considered an 
appropriate model to investigate epithelial response to injury, neutrophil 
infiltration or other aspects of the acute phase of colitis pathogenesis, but 
does not adequately address those events occurring during the chronic 
phase of gut inflammation.  
Immunological models. Immunologically mediated models are models of 
adoptively transferred T cells or bone marrow precursors, which are 
introduced into immunodeficient recipient mice. Two classical examples 
are the CD45RB
high
 [100] and bone marrow chimera transfer 
models[101]. Transfer of hsp60-reactive CD8þ T cells is also capable of 
inducing intestinal inflammation, primarily in the small intestine [102]. 
Studies in these models have elucidated the role of pathogenic and 
regulatory T cells in controlling mucosal immunity and intestinal 
inflammation and offer strong evidence that Th1 polarization plays a key 
role in CD pathogenesis. However, the profound immune abnormalities 
in recipient mice probably make these models unsuitable for 
investigating the innate factors causing human CD. 
Genetic models. Transgenic and knockout (KO) methodologies have 
revolutionized the field of animal models of IBD. The majority of the 
mouse models in this group are gene KO. Examples include the IL-2 
[103], TCRa/b [104], IL-10 [105], and Gi2-a [106] KO models. Genetic 
models greatly contribute to the understanding of the role of immune-
related molecules in the pathogenesis of chronic intestinal inflammation. 
However, it is unlikely that the imposed genetic mutations represent the 
underlying defect in human IBD, limiting the utility of these models for 
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understanding causative factors in both ulcerative colitis and CD. 
Spontaneous models. Spontaneous models represent one of the most 
attractive model systems for studying intestinal inflammation because, 
similar to human disease, inflammation occurs without any apparent 
exogenous manipulations. For example, the C3H/HeJBir murine model 
of colitis is characterized by spontaneous and chronic focal inflammation 
localized to the right colon and caecal region. Colitis occurs in young 
mice and tends to resolve with age without recurrence [107]. Similar to 
severely immunocompromised mice, as well as some of the KO mice, 
there appears to be a correlation between Helicobacter infection and the 
onset of colitis in the C3H/HeJBir model. 
 
2.2  Recent Advances in Genetics 
 
A major recent advance in the field of IBD has been made by human 
gene association studies that have identified many IBD-associated genes 
specific for either CD or UC or both. In particular, genomic wide 
association studies (GWAS) have highlighted the importance of genetic 
susceptibility in IBD. Interestingly, GWAS have revealed a substantial 
overlap in genetic risk factors between CD and UC [108]. However, 
some loci are quite unique for CD or UC. For example, autophagy genes 
(e.g., ATG16L1, IRGM), NOD-like receptors (e.g., NOD2), and 
intelectins (ITLN1) are highly specific for CD, whereas loci related to 
regulatory pathways (IL10 and ARPC2), intestinal epithelial cell (IEC) 
function (e.g., ECM1), and an E3 ubiquitin ligase (e.g., HERC2) appear 
to be specific for UC [109]. Moreover, GWAS have revealed genetic 
associations between IBD and many other immune-mediated disorders, 
which implies that a general inherited propensity to develop autoimmune 
diseases may exist and that environmental (or epigenetic) factors may 
determine not only disease phenotype but also the specific immune-
mediated disease that develops [110]. A striking but potentially 
instructive outcome of GWAS is that the vast majority of identified loci 
individually confer extremely modest risk [odds-ratios (ORs), mostly 
between 1.11 and 1.29]. Collectively, the loci identified to date represent 
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≈10–20% of the overall variance of potential disease risk. Moreover, for 
most of the confirmed loci the causal gene(s) or variant(s) is not yet 
known [111].  
Besides GWAS (and complementary to them), several KO mouse strains, 
which are genetically engineered to lack IBD-associated genes, have 
been developed. Among them, some mouse strains including IL-10 
[105], STAT3 [112], XBP1 [113], and GPX1/2 [114] KO mice and 
human HLAB27 transgenic rats [115] spontaneously develop colitis or 
ileitis. In contrast, the remaining IBD-associated gene KO mice fail to 
develop intestinal inflammation spontaneously, suggesting the 
requirement of additional factors such as immune and environmental 
factors to fully elicit the development of IBD. Of note, major IBD-
associated genes are classified into at least three groups, based on the 
biological function, including host defence, regulatory immunity, and the 
IL-23/Th17 axis. 
The NOD2 gene, which has been mentioned above, has the first 
definitive genetic risk factor identified for CD [63]. Three different 
mouse models harbouring non-functional NOD2 have been developed. 
The first mouse model, which carries a NOD22939insC mutation similar 
to the human CD-associated NOD23020insC frameshift mutation, is 
susceptible to DSS-induced intestinal injury [116]. Unlike chronic IBD 
models that do not develop disease under germ-free conditions, DSS-
induced acute intestinal injury is exacerbated in the absence of 
commensal flora [117]. Therefore, the increased susceptibility of NOD2 
mutant mice to DSS-induced intestinal injury suggests the involvement 
of NOD2 in commensal flora mediated protective immunity, particularly 
during the acute inflammatory phase. The second model is a NOD2 KO 
mouse strain generated by a deletion of exon 1. This mouse strain is 
characterized by TLR2 signalling. The production of IL-12p70 by APCs 
in this model is increased in response to TLR2 stimulation, suggesting an 
inhibitory role of NOD2 in TLR2-mediated Th1 responses [118]. The 
third model is another NOD2 KO mouse strain generated by deletion of 
exon 3. This mouse strain is more susceptible to a Listeria monocytogene 
infection because of impaired Paneth cell function and a reduced 
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production of antibacterial peptides such as cryptidin and defensins 
[119]. 
Autophagy is a cellular pathway involved in protein and organelle 
degradation. Recently accumulating data indicate that autophagy affects 
different physiological functions ranging from microbial infections to 
aging. An autophagy-related gene (Atg) 16L1 has been identified as a 
CD susceptibility gene and a deletion polymorphism upstream of IRGM, 
a gene essential for autophagy, is also associated with CD, highlighting 
the significance of autophagy in CD pathogenesis [108]. Two different 
mouse strains lacking functional Atg16L1 have been developed 
[120,121]. Both of the Atg16L1 KO mouse strains did not develop 
intestinal inflammation spontaneously, but one mouse strain with gene 
trap-mediated disruption of Atg16L1 showed an impaired Paneth cell 
function particularly the granule exocytosis process. These findings 
suggest that both NOD2 and Atg16L1 actively participate in epithelial 
cell defence against commensal flora. 
Accumulating evidence from animal models clearly indicates the 
protective role of IL-10 in IBD. Spontaneous development of colitis in 
IL-10 KO mice has been known since 1993 [105]. The possible clinical 
relevance of data from animal models is highlighted by a recent 
identification of the IL-10 as an IBD susceptibility gene [122]. The 
expression of Foxp3 in Treg cells is unstable in vivo and potential 
autoreactive effector T cells can develop from the Foxp3+ Treg cells as a 
consequence of loss of Foxp3. A recent study shows that myeloid cell-
derived IL-10 is required for maintaining Foxp3 expression in Treg cells 
and preserves the regulatory cell’s ability to suppress colitis [123]. It has 
been demonstrated that B cells are one of the major sources of IL-10 in 
the gut associated lymphoid tissue [124]. Although IL-10 KO mice 
spontaneously develop colitis, specific deletion of IL-10 in B cells does 
not result in colitis induction, consistent with the ability of IL-10-
producing Breg cells to inhibit the progression of established colitis but 
not the initial induction [125]. Although these findings would suggest IL-
10 as a therapeutic strategy for IBD, no apparent beneficial effect of IL-
10 therapy has been observed in several human clinical trials. Therefore, 
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it is possible that the polymorphisms of IL-10 receptors hamper the 
response of IBD patients to the IL-10 therapy [126]. Alternatively, the 
instability and short halflife of IL-10 may make the therapy less 
effective. 
In addition to a previously well appreciated Th1/Th2 paradigm, recently 
accumulating data has unveiled a critical involvement of the IL-23/Th17 
pathway in the pathogenesis of IBD [127]. A series of studies using IL-
23p19 KO mice or neutralizing anti-p19 mAbs have recently revealed the 
critical pathogenic role of IL-23, but not IL-12, in different types of 
experimental colitis, which are mediated by either adaptive or innate 
immunity. The clinical relevance of data from animal models is well 
supported by gene association studies in humans. Polymorphisms of the 
IL-23R are negatively associated with the development of IBD and IL-
12p40 has been identified as an IBD-associated gene. These findings 
highlight IL-23 (p19), rather than IL-12 (p40), as a promising target for 
treating IBD more effectively and more safely [128]. Although the 
involvement of the IL-23/IL-17 axis in IBD pathogenesis is a solid 
concept, recently accumulating studies from animal models suggest that 
the role of Th17 cells in IBD and the control of IL-17 prodution may be 
much more complicated than previously predicted. Paragraph 7 will deal 
with the evidence of Th17 and Th1/Th17 involvement in IBD, coming 
from both animal models and the most recent data from humans. 
 
 
3. Th17 and Th1/Th17 Cells: Beyond the Th1/Th2 
Paradigm 
 
Upon activation and expansion, CD4
+
 T cells develop into different Th 
cell subsets, with different cytokine profiles and distinct effector 
functions. The differentiation of naïve CD4
+ 
T cells into effector helper T 
cells is initiated by the engagement of their T cell receptor (TCR) and 
costimulatory molecules in the presence of specific cytokines produced 
by the innate immune system following the encounter of particular 
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pathogens. On the one hand, IFN-γ and IL-12 initiate the differentiation 
of Th1 cells that are characterized by high production of IFN-γ and are 
indispensable for clearing intracellular microorganisms [129]. On the 
other hand, IL-4 triggers the differentiation of Th2 cells, which produce a 
series of different cytokines, namely Il-4, IL-13 and IL-25, and organize 
host defence against extracellular pathogens and help B cells to produce 
antibodies [130]. Subsequently, the effector cytokines can potentially 
feed back to amplify Th1 and Th2 and further enhance differentiation of 
the respective T cell subset. Moreover, IFN-γ and IL-4 antagonize each 
other at different levels, and thus Th1 and Th2 development is 
considered mutually exclusive. Therefore, even though the cytokine 
profile may initially not be entirely polarized with differentiating T cells 
producing a combination of both Th1 and Th2 cytokines, chronic 
stimulation leads to unequivocal, terminally differentiated phenotypes. 
Over the years, the Th1/Th2 paradigm of T helper cell differentiation, 
which was first introduced by Mosmann & Coffman about 21 years ago 
[129], has explained many processes in adaptive immunity and allowed 
to classify immunological disorders as mainly Th1 (such as CD, multiple 
sclerosis, and rheumatoid arthritis) or Th2 (like UC, allergic dermatitis 
and asthma). Recently, this Th1/Th2 paradigm has been updated 
following the discovery of a third subset of IL-17-producing effector T 
helper cells, called Th17, which develop via a lineage distinct from the 
Th1 and Th2 lineages [131]. Th17 cells produce a variety of cytokines 
(namely IL-17A, IL-17F, IL-22, IL-26, IFN-γ), express the chemokine 
ligand (CCL)20, and the retinoic acid receptor-related orphan receptor 
(ROR)γt [132]; they can be characterized by the expression of a 
combination of chemokine receptor (CCR)4 and CCR6, and IL-23 
receptor (IL-23R) [133]. 
Although the function of this cell subtype is not completely elucidated, 
emerging data suggest that Th17 cells play an important role in host 
defence against extracellular pathogens, which are not efficiently cleared 
by Th1-type and Th2-type immunity. The first pathogen implicated in a 
Th17 response was observed in human Lyme arthritis caused by Borrelia 
burgdorferi, in which B. burgdorferi-derived lipopeptides could 
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stimulate the production of IL-17A by T cells from synovial fluid, 
leading to a Th17 lineage differentiation [134]. 
On the other hand, there is evidence that uncontrolled and persistent 
Th17 responses are responsible of tissue inflammation by producing IL-
17 and other effector cytokines (Figure 3) [135].  
Many chronically inflamed human tissues are infiltrated by highly 
differentiated Th17 lymphocytes [136], and IL-17 overexpression has 
been found in a number of inflammatory disorders, including IBD. In the 
murine model of psoriasis, evidence has shown that Th17 cells along 
with their upstream cytokines (e.g. IL-23) and their downstream effector 
cytokines (e.g. IL-22) might play a critical role in the pathogenesis of 
psoriasis [137,138]. Increased levels of IL-17 produced by Th17 cells 
have been observed in murine models of rheumatoid arthritis and 
correlate with more severe joint damage [139]. IL-17 is significantly 
high in the serum of patients with systemic lupus erythematosus [140], 
and contraction of Th17 cells has been associated with improvement in 
renal disease in mouse models of systemic lupus erythematosus using 
tolerizing peptides [141]. Elevated levels of IL-17 were detected in the 
blood and the cerebrospinal fluid of patients affected by multiple 
sclerosis [142]. Besides, several studies using the experimental 
autoimmune encephalomyelitis model in mice have suggested that IL-17 
may be a critical pathogenetic factor for multiple sclerosis [143, 144]. 
The role of IL-17 in allergic asthma has been largely studied [145,146], 
while emerging evidence shows that IL-17-producing cells are also 
involved in the pathogenesis of allergic dermatitis and contact 
hypersensitivity [147,148]. 
Three years ago an heterogeneous population of IL-17 and IFN- double-
producers belonging to the CCR6
+
CXCR3
+
 human memory T cell 
compartment, has been discovered [149]. This subset of cells show 
selective expression of IL-23R, CCR6 and the transcription factor 
RORγt, and they exhibit functional features, similar to those of the Th17 
clone, such as the ability to help B cells, low cytotoxicity, and poor 
susceptibility to regulation by autologous Treg cells. Subsequently, this 
emerging population of cells have been widely studied in multiple 
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diseases, and during the last three years experimental works have shown 
their involvement in plenty of immunological disorders and infections 
[150-152].  
 
 
4. Differentiation of Th17 Cells 
 
4.1 Cytokines Involved in Th17 Differentiation 
 
After T cell activation, the fine balance between the different T cell types 
is regulated by the cytokine environment. Differentiation of Th1 and Th2 
cells follows similar rules in human and mice; Th17 differentiation, in 
contrast, may not be as conserved. Initial studies in mice suggested that 
IL-23, a heterodimeric cytokine that shares the p40 subunit with IL-12, 
induces IL-17 expression [131,135,153]. However other studies 
demonstrated that IL-23R is only expressed on T cells after activation 
and therefore IL-23 can up-regulate IL-17 in memory T cells but cannot 
act on naïve T cells to induce Th17 differentiation [154]. In 2006, three 
independent research groups found that a combination of the 
immunoregulatory cytokine TGF-β and the pro-inflammatory and 
pleiotropic cytokine IL-6 is required to induce Th-17 differentiation in 
the mouse [155-157]. In addition, TNF-α and IL-1β can further enhance 
mouse Th17 differentiation, but only in the presence of TGF-β and IL-6 
[157-159]. This discovery was quite a surprise, because TGF-β is well 
known to inhibit most T cell responses as well as to induce 
differentiation of forkhead box protein 3 (Foxp3)-expressing regulatory 
T cells (Tregs). These conflicting effects of TGF-β, as an inducer of both 
anti-inflammatory Tregs and pro-inflammatory Th17 cells, raise a 
number of interesting questions about the role of TGF-β in physiologic 
differentiation of T helper cell subtypes, as well as in disease. In mice, 
Tregs can be a source of TGF-β for naïve Th17 differentiation, and one 
paper has demonstrated that Tregs themselves can convert into Th17 
cells in the presence of IL-6 [160]. Several studies show that TGF-β, a 
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crucial cytokine for mouse Th17 differentiation, actually inhibits human 
Th17 development [161,162]. Protocols used in previous human studies 
soon led to the doubt that TGF-β was not necessary to human Th17 
development (Figure 3). In fact, so far human naïve T cells were selected 
from CD45RA-expressing peripheral blood mononuclear cells. Besides, 
experiments were performed in the presence of serum and, giving that T 
cells were isolated from peripheral human blood, they were possibly 
contaminated with platelet (both source of TGF-β). Eventually, a series 
of new reports using rigorously sorted naïve T cells proved that TGF-β is 
indeed required for human Th17 differentiation [163-165]. These 
differences clearly demonstrate that a direct translation of knowledge on 
Th17 differentiation from mouse models to humans is impossible.  
One of the most effective inducer of IL-17 expression in human naïve T 
cells is IL-1β which on the contrary seems to play only a supporting role 
in mouse Th17 development. IL-6 and IL-23 induce a small amount of 
IL-17 alone and greatly enhance Th17 differentiation in the presence of 
IL-1β [132,162]. Thus, both IL-23 and IL-1β may play a more important 
role in humans than in mice (Figure 3). Cosmi et al. [166] demonstrated 
that all IL-17-producing cells originates from CD161
+
 naïve CD4
+
 T 
cells of umbilical cord blood, as well as postnatal thymus, in response to 
the combined activity of IL-1β and IL-23. Nevertheless, the potential role 
of IL-23 in human Th17 differentiation is still unclear, since other groups 
have found that IL-23 has no effect on naïve human T cells [153,167]. 
According to data obtained by Langrish et al. [153], IL-23 up-regulates 
IL-17 production and promotes survival and expansion of activated or 
memory Th17 cells in vitro, although it is not absolutely necessary. Also 
IL-21, which is produced by Th17 cells themselves, is known to be 
involved in Th17 differentiation in the presence of TGF-β. IL-21, acting 
in a positive feedback loop which amplifies the precursor frequency of 
Th17 cells, might help sustaining chronic inflammation in Th17-
dependent diseases (Figure 3) [168]. Last, but not least, IL-6 can 
program Th17 differentiation by promoting sequential engagement of the 
IL-21 and IL-23 pathways (Figure 3). Zhou et. al [169] demonstrated that 
IL-6 induces the expression of IL-21 that amplifies an autocrine loop to 
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induce more IL-21 and IL-23 receptor in naïve CD4
+
 T cells. 
 
 
 
Figure 3. Regulation of Th17 cells and their involvement in 
inflammation. T helper (Th)17 cells are a newly described subset of 
CD4
+
 T cells that may have a role in inflammatory disorders. These cells 
release interleukin-(IL)17A and IL-17F, which act on epithelial cells to 
release CXC-chemokine ligand 1 (CXCL1) and CXCL8, which attract 
neutrophils, and IL‑6, which enhances the activation of Th17 cells. Th17 
cells also release IL-21, which promotes Th17 cell differentiation via a 
positive autoregulatory loop involving the transcription factor signal 
transducer and activator of transcription (STAT3)3 and IL-22, which 
induces the release of IL-10 and acute-phase proteins. The regulation of 
Th17 cells is predominantly via IL-23 through the activation of the 
transcription factor retinoic acid receptor-related orphan receptor 
(ROR)γt, whereas transforming growth factor (TGF)β may have an 
inhibitory effect in human cells. TNF, tumour-necrosis factor. 
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4.2  Transcription Factors Involved in Th17 Differentiation 
 
The differentiation of T helper cells is initiated by the combined signals 
from the TCR, costimulatory molecules and cytokine receptors. These 
integrated signals then induce lineage-specific transcription factors. 
Among them, T-box expressed in T cells (T-bet) or trans-acting T-cell-
specific (GATA)-3 transcription factors are specifically and respectively 
expressed in Th1 and Th2 cells. In particular, T-bet can bind to the IFN-γ 
promoter and induces the expression of this cytokine. The engagement of 
IFN-γ leads to the activation of signal transducer and activator of 
transcription (STAT)1 and T-bet, responsible for Th1 cell differentiation. 
In turn, T-bet increases the production of IFN-γ and induces the 
expression of the inducible IL-12Rβ2 chain of the IL-12R. IL-12, 
through STAT4, is then essential for the maintenance of Th1 responses. 
On the other hand, GATA-3 starts a Th2 cell lineage commitment and 
induces the expression of IL-4. The interaction of IL-4 with its receptor 
activates STAT6, which together with GATA-3 increases IL-4 
production and Th2 commitment. 
It has been found that RORγt is the master transcription factor guiding 
Th17 differentiation in mice [170]. RORγt appears to be required for IL-
17 production (Figure 3), as mice reconstituted with the bone marrow of 
RORγt-deficient mice show an impaired Th17 differentiation. 
Furthermore, transduction of naïve T cells with a retroviral vector 
containing RORγt induces the development of IL-17-producing T cells 
[170]. However, although reduced, IL-17-producing cells are not absent 
in RORγt-deficient mice. Another member of the retinoid nuclear 
receptor family, RORα, is also selectively expressed in Th17 cells [171]. 
RORγt and RORα are both strongly induced by IL-6 or IL-21 in the 
presence of low amounts of TGF-β. Recent studies reported that other 
transcription factors cooperate with RORγt in Th17 development. For 
example, the interferon regulatory factor (IRF)4, which was previously 
associated with the differentiation of the Th1 and Th2 subsets [172], is 
required for the differentiation of Th17 cells as well [173]. IRF4 
knockout mice failed to mount a Th17 response and were resistant to 
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experimental encephalomyelitis. Consistently, IRF4-deficient T cells 
failed to up-regulate RORγt upon stimulation in the presence of TGF-β 
plus IL-6, and could not be differentiated into Th17 cells. However, 
overexpression of RORγt in IRF4-deficient T cells failed to fully restore 
the induction of IL-17, again suggesting that RORγt is not sufficient for 
full commitment of T cells to the Th17 lineage. Another transcription 
factor regulating IL-17 production is STAT3 [174] (Figure 3). Mice with 
conditional deficiency of STAT3 in T cells have impaired Th17 
differentiation, and overexpression of a constitutively active form of 
STAT3 can increase IL-17 production. Thus, STAT3 might affect the 
expression of IL-17 by increasing the expression of RORγt and RORα, 
which are upstream of IL-17. However, STAT3 also binds directly to the 
IL-17 and IL-21 promoters [175]. Therefore, STAT3 and RORγt seem to 
cooperate, and competent production of IL-17 depends on the presence 
of both transcription factors. Finally, Th17 are closely linked to Foxp3
+
 
Treg cells, as it has been shown that both cell types require TGF-β for in 
vitro differentiation and that Foxp3 controls Th17 differentiation by 
direct interaction with RORγt [161,176]. Just after the discovery of the 
transcription factors involved in mouse Th17 differentiation, Manel et al. 
[164] demonstrated that RORc, which corresponds to RORγt in humans, 
is crucial for Th17 development. Since down-regulation of RORc 
through transient transfection with short hairpin RNA molecules in 
memory CCR6
+
 cells resulted in much less IL-17 expression, it is clear 
that RORc is required for the maintenance of cytokine production in 
Th17 cells. 
 
 
5. Trafficking of Th17 Cells 
 
Th17 cells cause inflammation and immune disorders through both pro-
inflammatory cytokines and chemokines with their chemokines 
receptors, which mediate trafficking of activated T cells into inflamed 
tissue. Several reports have found that human and mouse Th17 cells 
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express CCR6. Within this population those cells that coexpress CXCR3 
are either Th1 or IFN-γ/IL-17 double-positive, while those that coexpress 
CCR4 are classical Th17 expressing only IL-17 [133,177]. In addition, 
the majority of RORc expression was restricted to CCR6
+
CCR4
+
 
population, with a small amount in the CCR6
+
CCR3
+
 population [133]. 
CCR6 mediates homing to skin and mucosal tissues and has been shown 
to play an important role in recruitment of pathogenic T cells in many 
inflammatory diseases now associated to IL-17, including psoriasis, IBD, 
allergic asthma and rheumatoid arthritis [177-181]. Interestingly, the 
CCR6 ligand CCL20 is expressed on Th17 cells and is up-regulated on 
stromal cells by IL-17, thus allowing Th17 cells in inflamed tissue to 
attract additional Th17 and Th1 cells [132,182]. 
 
 
6. IL-17 
 
IL-17, which has been known for years before Th17 cells were 
discovered, is the founding member of the IL-17 family of cytokines, 
which includes IL-17A (also called IL-17), IL-17B, IL-17C, IL-17D, IL-
17E (also called IL-25), and IL-17F [183]. Whereas all members of the 
IL-17 family are produced by Th17 cells, IL-17E derives from Th2 cells 
[130]. IL-17A and IL-17F are syntenic, as they co-localize on the same 
chromosome (chr.1 in mice; chr.6 in humans); conversely, the other IL-
17 cytokines map to different chromosomes. IL-17 shares no sequence 
homology with other known mammalian proteins and therefore 
constitutes a distinct cytokine family. IL-17A and IL-17F are effector 
cytokines produced not only by Th17 cells, but also γδ T cells, natural 
killer (NK)T cells, neutrophils, eosinophils and NK cells [184]. This 
suggests that IL-17 cytokines may have a bridging function between 
innate and adaptive immune responses.  
 IL-17A binds to IL-17 receptor (IL-17R) with more than ten-fold higher 
affinity as compared to IL-17F, and acts on both immune and non-
immune cells. IL-17R is expressed on a wide range of cells, including 
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osteoblasts, fibroblasts, epithelial and endothelial cells [185]. IL-17 
induces pro-inflammatory cytokine production by macrophages, thus 
creating a link between innate and adaptive immunity [186],
 
and plays a 
key role in host defence against bacteria and fungi, particularly at 
mucosal surfaces (Figure 4), by favouring the local recruitment of 
immune cells [187]. Consistently, mice knockout for the IL-17R gene 
have profound defects in host protection [188]. 
Involvement of IL-17 in inflammation is now well documented: ligation 
of IL-17 with its receptor promote the synthesis of a broad variety of 
inflammatory cytokines (e.g. IL-1, IL-6, TNF-α, GM-CSF), chemokines 
(e.g. IL-8, CXCL1, CXCL8, monocyte chemoattractant protein-1, 
monocyte inhibitor protein-(MIP)3α), cyclooxygenase-2, and tissue 
degrading matrix metalloproteinases (MMPs) by several cell types [189]. 
In particular, IL-17 induces IL-6 and IL-8 production in vitro through 
mitogen-activated protein kinase (MAPK) pathways, thus favoring the 
recruitment of neutrophils at sites of inflammation [77], and triggers T 
cell proliferation and up-regulation of pro-inflammatory molecules, such 
as inducible nitric oxide synthase and IL-1 [190]. Interestingly, some 
actions of IL-17 are potentiated by the presence of other pro-
inflammatory cytokines, particularly TNF-α and IL-1. 
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Figure 4. Role of Th17 cells in the modulation of intestinal inflammation. 
Th17 cells differentiate from naïve T lymphocytes under the stimulus of 
TGF-β and IL-6, while the antigen antigen-presenting cells-derived IL-
23 and the Th17 cell-derived IL-21 contribute to maintain/expand Th17 
cell populations. Th17-derived cytokines, such as IL-17A, IL-21, and IL-
22 are involved in the recruitment of inflammatory cells in the intestinal 
lamina propria, due to their ability to enhance the expression of 
chemoattractants and adhesion molecules (e.g. ICAM-1) by epithelial 
and endothelial cells, respectively. IL-17A and IL-21 stimulate 
fibroblasts to make matrix metalloproteinases, a family of enzymes that 
could contribute to the tissue damage and remodelling occurring in IBD. 
IL-17A and IL-22 also stimulate the synthesis of antibacterial proteins, 
including defensins, by epithelial cells. APC, antigen antigen-presenting 
cell; TGFβ, transforming growth factor-β; MMPs, matrix 
metalloproteinases; ICAM-1, intercellular adhesion molecule-1. 
 
 
7. Th17 and Th1/Th17 Cells in IBD: Beyond Th1 and 
Th2 Responses 
 
It is well known that CD is characterised by a preponderance of Th1-
associated cytokines, including IFN-, TNF-α and IL-12, while Th2 
cytokines, such as IL-5 and IL-13, are considered to be dominant in UC 
[75]. Nonetheless, both CD and UC share crucial end-stage pathways, as 
shown by the enhanced production of IL-21 and IL-23 in both disorders 
[79,191]. 
The role of Th1 cells in the pathogenesis of CD is well established, based 
on a number of observations, including the increased production of IL-12 
in macrophages in this condition [192]. Moreover, nuclear extracts of T 
cells isolated from the inflamed gut areas of CD patients contain high 
levels of activated STAT4 and T-bet, Th1-associated transcription 
factors (see above) indicative for IL-12 signalling [193]. Furthermore, in 
the mucosa of patients affected by CD there is an enhanced production of 
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IL-18, a cytokine involved in perpetuating Th1 cell responses [194]. In 
addition, T cells from inflamed gut tissue of CD patients express 
increased levels of IL-12Rβ2 chain, which is characteristic for Th1 cells, 
and increased amounts of IFN-γ together with decreased levels of IL-4 
compared to controls [74,195]. IFN-γ secreting lamina propria 
lymphocytes are abundant in the mucosa of patients with CD. 
Particularly, at onset of the disease mucosal T cells appear to mount a 
typical Th1 response that resembles an acute infectious process, and is 
lost with progression to late CD [196]. In addition, a clinical response 
was observed in a subcohort of CD patients treated with anti-IFN-γ 
monoclonal antibody [34]. 
By contrast, T cells from lamina propria of patients affected by UC 
produce a higher amount of IL-5 in comparison to CD and controls [74]. 
Moreover, Heller et al. [75] demonstrated that IL-13 is the key effector 
Th2 cytokine in UC that affects epithelial tight junctions, apoptosis and 
cell restitution. 
In the last decade, several studies indicated that, in addition to Th1 
lymphocytes, Th17 cells play a major role in the pathogenesis of CD, and 
possibly even of UC.   
 
7.1  Th17 in Mouse Models of Gut Inflammation 
 
Studies in IL-17R knockout mice demonstrated that IL-17 is necessary 
for the development of acute gut inflammation induced by intrarectal 
administration of TNBS [197], a T cell-mediated colitis showing striking 
similarities with CD. Consistently, blockade of IL-17 signalling by an 
IL-17R IgG1 fusion protein significantly attenuated colonic 
inflammation and prevented weight loss after TNBS administration in 
mice. Studies in other animal models of colitis such as DSS-induced 
colitis showed that IL-17F deficiency results in reduced colitis, whereas 
IL-17A knockout mice develop more severe disease [198], suggesting 
that IL-17F rather than IL-17A is crucial in sustaining inflammation in 
chemical-induced colitis. Th17 cells have been also involved in the 
pathogenesis of colitis induced by transfer of caecal bacterial antigen-
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specific C3H/HeJBir (C3Bir) CD4
+
 T cell line to C3H/HeSnJ SCID mice 
[199]. In this model, gut inflammation associated with enhanced 
production of IL-17, and adoptive transfer of IL-17-secreting T cells to 
SCID recipients resulted in a marked gut inflammation, as compared to 
that caused by transfer of Th1 cells. Administration of mice with a 
monoclonal anti-IL23p19 prevented and treated active colitis. By using a 
novel model of CD8
+
 T cell-dependent colitis, Tajima et al. [200] have 
shown that a single adoptive transfer of naïve CD8
+
 T cells into 
syngeneic RAG-deficient mice was followed by rapid spontaneous 
proliferation of these cells in the mesenteric lymph nodes and severe 
colitis. Analysis of cytokine-secreting CD8
+
 T cells in the mesenteric 
lymph nodes showed the existence of IL-17/IFN-γ double-positive cells. 
Notably, adoptive transfer of naïve CD8
+
 T cells derived from either IL-
17- or IFN-γ-knockout mice associated with a remarkably less severe 
colitis, raising the intriguing possibility that IL-17 and IFN-γ can 
cooperate to cause pathology in this model of colitis. In line with these 
findings, Fina et al. [78] recently demonstrated that IL-21-deficient mice 
were largely protected against the development of DSS colitis and 
TNBS-relapsing colitis. This protection was associated with a reduced 
colonic expression of several Th17-related genes, including IL-17A, IL-
17F, and RORγt, supporting the role of IL-21 in Th17 cell 
differentiation. Additionally, blockade of IL-21 activity with a specific 
IL-21R fusion protein reduced intestinal inflammation and Th17 
response during the course of DSS colitis. 
After the demonstration that blockade of IL-12/IL-23p40 ameliorated 
colitis in mice [201], a monoclonal antibody against IL-12p40 was used 
in a phase II trial to treat patients with active CD leading to good results 
[202]. Since the p40 subunit is shared by both IL-12 and IL-23 [203], it 
was not clear if the therapeutic effect of this novel reagent was due to 
neutralization of IL-12 and/or IL-23. However, studies conducted in 
various animal models of colitis would seem to indicate that IL-23 is 
more pathogenic than IL-12 in the gut. For instance, backcrossing IL-10-
deficient mice with mice lacking IL-12p35 or IL-23p19, Yen et al. [204] 
showed that IL-23 was essential for manifestation of chronic intestinal 
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inflammation, whereas IL-12 was not. CD4
+
 T cells from IL-10p19 
knockout mice still produced large amounts of IFN-γ, thus indicating that 
Th1 response developed normally in the absence of IL-23 but disease 
manifestations required the presence of IL-23. Moreover, administration 
of exogenous IL-23 in RAG mice reconstituted with naïve CD4
+
 T cells 
caused a more severe colitis that was associated with enhanced 
production of IL-6 and IL-17 and preventable by treatment of mice with 
a blocking IL-6 or IL-17 antibody. Although in this model IL-6 and IL-
17 were made by memory T cells, there is no doubt that some of the 
pathogenic functions of IL-23 in the gut are mediated by a non-T cell 
population. This was first showed by Powrie and coworkers who 
analysed the effect of an agonistic anti-CD40 antibody in RAG mice IL-
23p19 or IL-12p35 [205]. Administration of anti-CD40 caused a 
systemic and local inflammation characterized by wasting disease, 
spenomegaly, increases in serum pro-inflammatory cytokines and colitis. 
It was shown that the systemic inflammatory response and the elevated 
concentration of pro-inflammatory cytokines in the serum were derived 
by IL-12 while the local intestinal inflammation and production of IL-17 
in the intestine were controlled by IL-23. More recently using the T cell 
transfer model of colitis the same group has shown that IL-17-deficient T 
cells are not impaired in their ability to induce colitis in RAG mice [206]. 
Protection of colitis seen in RAG mice lacking IL-23 was associated with 
no decreases in the levels of IL-17, as well as lack of IL-23 did not 
significantly affected the relative amount of the Th17-specific factor 
RORγt in the colon. Consistent with this study, Noguchi et al. [207] 
showed that transfer of naïve CD4
+
 T cells prepared from IL-17 
knockout mice induced severe colitis in RAG mice. Taken together this 
data indicate that Th17 cell responses are not specifically impaired in the 
intestine of IL-23-deficient mice and that IL-23-mediated colitis is not 
strictly dependent on IL-17 production. 
A more detailed analysis of the mechanisms underlying the IL-23-
dependent pathologies revealed that IL-23 can facilitate colitis not only 
via direct effect on inflammatory mediators but also indirectly by 
counteracting regulatory mechanisms. Indeed, protection of colitis seen 
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after transfer naïve T cells to RAG mice lacking IL-23 was associated 
with an increase in the frequency of Foxp3-expressing Treg cells in the 
intestine [206]. Upon naïve T cell transfer administration of mice with 
either an antagonistic IL-10R antibody or a blocking TGF-β antibody 
increased colonic inflammation compared to untreated controls. 
Moreover, naïve T cells isolated from transgenic mice expressing a 
dominant-negative form of TGF-β receptor II and unable to respond to 
TGF-β induced significant colitis when transferred to IL-23-deficient 
RAG mice [206]. High levels of IFN-γ but not IL-17 were seen in colitis 
mice, thus suggesting that IFN-γ might drive the chronic intestinal 
inflammation in this setting. Notably, transfer of Foxp3-deficient T cells 
to IL-23-deficient RAG mice caused severe colitis, thus indicating that 
IL-23 is not essential to the pathogenesis of intestinal inflammation, if 
counter regulatory mechanisms are defective or absent [206]. These later 
findings well fit with the notion that the requirement of IL-23 for the 
initiation and progress of gut inflammation varies depending on the 
model. In fact, acute colitis induced by TNBS is driven by IL-12 and 
negatively regulated by IL-23 [208].  
 
7.2 Th17 in Human Gut Inflammation 
 
The first report on IL-17-producing cells in IBD comes from a study in 
which it was shown that the inflamed gut of CD and UC patients 
contained high levels of IL-17-secreting cells in comparison to normal 
controls or patients with ischemic colitis [76]. By 
immunohistochemistry, it was shown that in active UC IL-17-expressing 
cells were located mainly within the lamina propria, while in active CD 
these cells were scattered throughout the submucosa and muscolaris 
propria. Major sources of IL-17 were CD3
+
 T cells and CD68
+
 cells. 
Moreover, IL-17 was found to be enhanced in the serum of IBD patients. 
These results were confirmed by the demonstration that RNA transcripts 
for IL-17A and IL-17F were up-regulated in the inflamed mucosa of UC 
and CD patients [76,209]. By flow cytometric analysis of mucosal 
lymphocytes, Annunziato et al. [149] demonstrated that the number of 
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IL-17-producing T cells is higher in CD than in normal gut mucosa, and 
that some of these cells produce also IFN-γ. In vitro treatment of such 
cells with IL-12 resulted in enhanced expression of T-bet and IFN-γ, and 
down-regulation of RORγt and IL-17. Therefore if at one side it seems 
that Th1 negatively cross-regulates Th17 differentiation, on the other 
hand the above findings suggest that T cells can coexpress both Th1- and 
Th17-cytokine signatures, which are equally involved in gut 
inflammation. Hence, the interactions between Th1 and Th17 cells and 
the role of IFN-γ on Th17 cells may be more complex than previously 
assumed and require further analysis to delineate the specific 
contribution of these cell lines to CD and other autoimmune diseases. 
Of note, the inflamed mucosa of IBD patients contains high levels of 
other Th17-related cytokines. In both CD and UC tissue there is 
enhanced production of IL-21, a cytokine that is capable of regulating the 
activity of multiple immune and non-immune cell types [191]. Indeed, 
IL-21 has been reported to expand the ongoing Th1 cell response in CD 
[191], to stimulate gut fibroblasts to secrete MMPs [210], and to induce 
colonic epithelial cells to produce MIP-3α [211], a chemokine involved 
in the recruitment of activated T cells and dendritic cells in the gut 
(Figure 4). IL-22 is also highly expressed in mucosal samples of patients 
with active CD and to a lesser degree of patients with UC [212]. Like 
other Th17 members, IL-22 stimulates colonic fibroblasts to make 
inflammatory cytokines (e.g. IL-6, IL-8, IL-11, and leukemia inhibitory 
factor), chemokines, and MMPs [212]. Moreover, IL-22 enhances the 
expression of TNF-α, IL-8, and β-defensin [213] (Figure 4). By using an 
in vitro wounding assay Brand et al. [213] showed that IL-22 stimulates 
the migration of colonic cells by a PI-3 kinase-dependent mechanism, 
thus suggesting that IL-22 promotes disruption of intestinal barrier 
integrity. Again, the same group demonstrated that IL-26, the novel Th17 
cytokine, is increased in the gut of CD patients and derives from RORγt-
expressing cells [214]. 
46 
 
Main Project  
 
1. Aim 
 
Even though it is clear that IL-17 is involved in gut inflammation, 
contrasting data are available on its role and regulation in CD and UC. 
Kobayashi et al. [215] detected high levels of IL-17 transcripts in both 
CD and UC mucosa compared to normal gut. This group also found that 
high IL-23p19 transcript levels correlated with IL-17 levels in UC and 
IFN- in CD, thus concluding that IL-23 differentially regulates the 
Th1/Th17 balance in UC and CD. In contrast, as mentioned before, 
Fujino et al. [76] showed by immunohistochemistry that there was higher 
IL-17 expression in CD than UC mucosa. Nevertheless, the 
demonstration by Fuss et al. [216] that IL-23 is up-regulated in CD but 
not UC further confuses the picture, and makes it difficult to understand 
the control of IL-17 production in UC. As reported before, a number of 
studies have examined the role of different cytokines in inducing IL-17 
by virgin CD4
+
 T cells. A role for IL-1, IL-6 and TGF- in polarizing 
Th17 cells in man is clear,
 
but the contribution of these cytokines to IL-
17 production in the gut is not known. Again, it is well known that IL-12 
is up-regulated in IBD and induces an increase of IFN- production by 
Th1 cells [217]. However, its influence on IL-17-producing lamina 
propria mononuclear cells (LPMCs) has not been investigated. Finally, 
IL-21 also seems to be implicated in the regulation of IL-17 production 
by lamina propria lymphocytes according to preliminary work by Fina et 
al. [78], but its role needs to be further elucidated. 
Moreover the novel subset of CD4
+ 
T cells, namely Th1/Th17 cells, 
which produce both IFN- and IL-17, has been shown to originate from a 
CD161
+ 
CD4
+
 NK T cell precursors present in the umbilical cord blood, 
in the presence of IL-1 and IL-23 as polarizing cytokines, but whether 
this pathway is important in vivo in man is not known.  
Main hypothesis. Our hypothesis was that chronic inflammation in IBD 
is sustained by effector cytokines produced by three different populations 
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of T cells: Th1, Th17 and Th1/Th17. Moreover, we believed that these T 
cell subsets were differentially regulated by pro-inflammatory and anti-
inflammatory cytokines involved in controlling human gut inflammation. 
How hypothesis has been tested. In order to clarify these issues, we first 
determined the production of IL-17 and IFN-γ in the supernatants of 
organ and cell cultures by using intestinal mucosal biopsies of IBD 
patients (ex vivo and in vitro experiments). Second, we analyzed lamina 
propria Th1, Th17 and Th1/Th17 populations in IBD patients through 
flow cytometry. Third, we investigated the control of IL-17 and IFN-γ 
production by IBD LPMCs after stimulation with a series of pro-
inflammatory (IL-23, IL-1β, IL-6) and anti-inflammatory (TGF-β) 
cytokines, or blocking monoclonal antibodies such as the anti-human IL-
21. 
 
 
2. Materials and Methods  
 
2.1 Patients and Tissues 
 
Colonic biopsies or surgical specimens were taken from macroscopically 
and microscopically inflamed and uninflamed areas of the mucosa of 38 
patients affected by CD (Table 3) and 34 patients affected by UC (Table 
4). Diagnosis of CD and UC was ascertained according to the usual 
clinical criteria, and the site and extent of the disease were confirmed by 
endoscopy and histology. In CD patients, disease activity was assessed 
by Crohn’s Disease Activity Index. Patients with scores below 150 were 
classified as being in remission, whereas those with scores over 450 had 
severe disease [218]. In UC patients, disease activity was assessed 
according to the Clinical Activity Index of Rachmilewitz [219]. Clinical 
remission was defined as a score below 4. None of IBD patients had been 
ever treated with cyclosporine, tacrolimus or anti-TNF antibodies. 
Mucosal samples were also collected from the colon of 27 subjects who 
had functional diarrhoea at the end of their diagnostic work-up (mean 
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age 38.1 years, range 29-68), and from macroscopically and 
microscopically unaffected colonic areas of 11 patients undergoing 
colectomy for colon cancer (mean age 51 years, range 39-70). In order to 
exclude that results were simply due to an unspecific gut inflammation, 
instead of IBD-related inflammation, we included a positive control 
group of gut inflammation in the study. Therefore, biopsy specimens 
taken from the inflamed mucosa of a patient with radiation colitis, two 
patients with diverticulitis and two patients with ischemic colitis were 
used as disease controls (non-IBD patients). Some of the mucosal 
samples were used to isolate LPMCs, some others for organ culture 
experiments. Each patient who took part in the study was recruited after 
appropriate local Ethics Committee approval, and informed consent was 
obtained in all cases. 
 
Table 3. Clinical features of patients with Crohn’s disease (n=38) 
Characteristics and parameters N. Median (range) 
Age (years) 
First attack 
Intestinal location 
                    Small bowel and colon 
                    Colon only 
Disease behaviour 
                     Fistulizing 
                    Stricturing 
                    Luminal 
Duration of disease (months) 
Number of recurrences 
CDAI 
Treatment 
                    Mesalazine 
                    Mesalazine + topical steroids 
                    Mesalazine + antibiotics 
                   Mesalazine + azathioprine/6-          
MP/methotrexate 
5 
 
28 
10 
 
5 
   9 
  
24 
 
 
 
 
15 
5 
9 
6 
32.1 (15-63) 
 
 
 
 
 
 
 
 
75.3 (1-223) 
2.2 (0-6) 
191 (87-394) 
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Table 4. Clinical features of patients with ulcerative colitis (n=34) 
Characteristics and parameters N. Median (range) 
Age (years) 
First attack 
Intestinal location 
                    Pancolitis 
                    Left-sided colitis 
Duration of disease (months) 
Number of recurrences 
CAI 
Treatment 
                     Mesalazine 
                     Mesalazine + topical steroids 
                     Mesalazine + azathioprine/6-MP 
 
4 
 
14 
20 
 
 
 
  
7 
13 
5 
     35.6 (14-53) 
 
 
 
 
         68.5 (1-191) 
2.4 (0-5) 
  6.1 (1-12) 
 
 
2.2 Organ Culture 
 
Biopsy specimens were placed on iron grids in the central well of an
 
organ culture dish and the dishes placed in a tight chamber
 
with 
95%O2/5%CO2 at 37°C [220]. Serum-free HL-1 medium (Cambrex Bio 
Science, Wokingham, UK), added with 100 U/ml penicillin and 100 
g/ml streptomycin, was used to assess the spontaneous cytokine 
production by biopsies grown ex vivo. After 24h culture, supernatants 
were snap frozen and stored at -70°C. 
 
2.3 Cell Isolation 
 
LPMCs were isolated and purified from freshly resected surgical
 
specimens or endoscopic biopsies as previously described [220]. The 
epithelial layer was removed with 1 mM EDTA (Sigma-Aldrich, Poole, 
UK). After stirring for 1h at 37°C, the supernatant was removed and the 
remaining tissue was treated with type 1A collagenase (1 mg/ml; Sigma-
Aldrich) for 2h with stirring at 37°C. The resulting crude cell suspension 
was preferentially enriched
 
for intestinal LPMCs using a Ficoll-Paque 
Plus gradient (Amersham
 
Pharmacia Biotech, Uppsala, Sweden) 
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following the manufacturer’s protocol. Cells from the supernatant were 
washed twice, resuspended in 1 ml RPMI-1640 medium (Sigma-Aldrich) 
containing 10% fetal calf serum, 100 U/ml penicillin and 100 g/ml 
streptomycin, and kept on ice until used. Cells were not used if viability 
did not exceed 90%. 
 
2.4 Cell Culture 
 
Freshly isolated LPMCs (2x10
5
 cells/well) were stimulated in anti-CD3-
coated 96-well plates (BD Biosciences, Oxford, UK) with soluble anti-
CD28 antibody (0.5 g/ml; eBioscience, San Diego, CA), and incubated 
for 48h with medium containing IL-1 (10 ng/ml) plus IL-6 (20 ng/ml), 
IL-23 (10 ng/ml), IL-12 (5 ng/ml), TGF-1 (10, 1, 0.1 and 0.01 ng/ml), a 
mouse anti-human IL-21 neutralizing antibody (20 g/ml; kindly 
provided by Giovanni Monteleone) or its isotype control (mouse IgG). 
All the above mentioned recombinant human cytokines were from R&D 
System (Minneapolis, MN). For intracellular cytokine staining, purified 
LPMCs were stimulated for 4h in RPMI complete medium with phorbol 
12-myristate 13-acetate (PMA, 50 ng/ml; Sigma-Aldrich) and ionomycin 
(500 ng/ml; Sigma-Aldrich) in the presence of monensin (2 M; 
eBioscience). 
 
2.5 ELISA 
 
Concentrations of IL-17 and IFN- in organ culture and LPMC 
supernatants were measured using specific ELISA kits (R&D System), 
according to the manufacturer’s instructions. 
 
2.6 Flow Cytometry 
 
Surface-staining of LPMCs was performed at 4°C for 30 min with FITC-
conjugated anti-CD3 and APC-conjugated anti-CD161 antibodies (BD 
Biosciences). After fixation with 100 l Leucoperm A, and 
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permeabilization with 100 l Leucoperm B (Serotec, Oxford, UK), PE-
conjugated anti-IL-17 and PE-Cy5-conjugated anti-IFN- antibodies (BD 
Biosciences) were added for 30 min. Appropriate isotype-matched 
control antibodies were purchased from BD Biosciences and included in 
all experiments. After washing twice with 250 l fluorescence-activated 
cell sorter buffer (phospate buffer containing 1 mM EDTA and 0.02% 
sodium azide), cells were fixed with 2% paraformaldehyde and analysed 
by flow cytometry using a FACSAria II Flow Cytometer (BD 
Biosciences). 
 
2.7 Statistical Analysis 
 
Data were analyzed in the GraphPad Prism statistical PC program 
(GraphPad Software, San Diego, CA) using the paired t test for 
independent samples and the non parametric Mann-Whitney U test (see 
figure legends). A level of p<0.05 was considered statistically 
significant. 
 
 
3. Results 
 
3.1 Ex vivo Production of IL-17 and IFN- 
 
First, we aimed to determine the spontaneous production of IL-17 and 
IFN- by organ culture biopsies from the inflamed and uninflamed 
mucosa of 17 IBD patients (7 with CD and 10 with UC) and normal 
mucosa of 10 control subjects (Figure 5). The concentration of IL-17 was 
significantly higher in the supernatants of both CD (mean 188  50 
pg/ml, p<0.01) and UC organ culture biopsies (mean 130  47 pg/ml, 
p<0.05) in comparison to controls (mean 27  5 pg/ml). Uninflamed 
mucosa from CD and UC patients showed significantly lower levels of 
IL-17 in comparison to inflamed mucosa (CD: mean 36  11 pg/ml, 
p<0.01; UC: mean 48  14 pg/ml, p<0.05). Likewise, the concentration 
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of IFN- was significantly higher in the supernatants of both CD (234  
53 pg/ml, p<0.01) and UC organ culture biopsies (201  49 pg/ml, 
p<0.01) in comparison to uninflamed areas (CD: mean 79  24 pg/ml, 
p<0.01; UC: mean 69  18 pg/ml, p<0.01) and controls (23  6 pg/ml). 
No significant difference was observed in the production of IL-17 and 
IFN- between CD and UC patients. 
 
 
 
Figure 5. Levels of IL-17 and IFN-, expressed in pg/ml, in the 
supernatants of biopsies taken from the inflamed and uninflamed colon 
of 7 Crohn’s disease (CD) patients and 10 ulcerative colitis (UC) 
patients, and from the normal colon of 10 healthy controls (HC), and 
cultured for 24h in the absence of stimuli. Data were analyzed using the 
Mann-Whitney U test. Results are mean  SD. *p<0.01 versus HC and 
uninflamed areas of CD and UC; **p<0.05 versus HC and uninflamed 
areas of CD and UC.  
 
3.2 In vitro Production of IL-17 and IFN- 
 
We then determined the production of both IL-17 and IFN- from 
unstimulated and anti-CD3/CD28-stimulated LPMCs isolated from the 
inflamed mucosa of 28 IBD patients (14 with CD and 14 with UC) and 
the inflamed mucosa of 5 non-IBD patients (one with radiation colitis, 
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two with diverticulitis and two with ischemic colitis), and the normal 
mucosa of 14 control subjects (Figure 6). In unstimulated conditions, 
LPMCs from CD and UC patients produced significantly (p<0.05) higher 
amounts of IL-17 (mean 862  372 pg/ml and 644  385 pg/ml, 
respectively) in comparison to control LPMCs (mean 92  11 pg/ml) and 
LPMCs from non-IBD patients (mean 124  25 pg/ml). No difference 
was found between control subjects and non-IBD patients, and between 
CD and UC. Activation with anti-CD3/CD28 antibodies significantly 
enhanced the LPMC production of IL-17 in comparison to unstimulated 
conditions in all the four groups, particularly in IBD patients (CD: mean 
6421  1869 pg/ml, p<0.001; UC: mean 4696  2049 pg/ml, p<0.001; 
control subjects: 1795  583 pg/ml, p<0.01; non-IBD patients: 2099  
497 pg/ml, p<0.01). No significant difference was found in CD3/CD28-
stimulated LPMC production of IL-17 between control subjects and non-
IBD patients, and between CD and UC patients. Unstimulated LPMCs 
from CD patients, UC patients and non-IBD patients produced 
significantly (p<0.05) higher amounts of IFN- (mean 710  212 pg/ml; 
544  161 pg/ml; and 503  143 pg/ml, respectively) in comparison to 
control LPMCs (mean 188  109 pg/ml). After stimulation with anti-
CD3/CD28 antibodies, IFN- production was significantly enhanced in 
comparison to unstimulated conditions in all the four groups, particularly 
in IBD patients and non-IBD patients (CD: mean 7101  2099 pg/ml, 
p<0.001; UC: mean 5764  2038 pg/ml, p<0.001; non-IBD patients: 
5532  2391 pg/ml; p<0.001; control subjects: 2848  851 pg/ml, 
p<0.01). Of note, if cytokine levels in LPMC supernatants were 
expressed as the ratio between values in medium only and values after 
anti-CD3/CD28 stimulation, the increase of IL-17 or IFN-γ production 
was higher in controls than IBD patients (Figure 6, lower panel). This is 
not surprising giving that IL-17 and IFN-γ production were already high 
in unstimulated conditions. Consequently, the ratio is lower in IBD 
patients than control subjects, whose LPMCs hardly produce both 
cytokines in unstimulated conditions. As far as the non-IBD patient 
group is concerned, it seems that stimulation enhances IL-17 more than 
54 
 
IFN-γ, which in fact looks already quite upregulated in unstimulated 
conditions, similarly to the IBD group.  
 
 
 
                
Figure 6. Upper panel. Levels of IL-17 and IFN-, expressed in pg/ml, in 
the supernatants of unstimulated and anti-CD3/CD28-stimulated LPMCs 
isolated from the inflamed colon of 14 Crohn’s disease (CD) patients, 14 
ulcerative colitis (UC) patients, and 5 non-IBD patients (1 with radiation 
colitis, 2 with diverticulitis and 2 with ischemic colitis), and from the 
normal colon of 14 healthy controls (HC), and cultured for 48h. Data 
were analyzed using the Student’s t test. Results are mean  SD. †p<0.05 
versus unstimulated HC LPMCs; 
§
p<0.01 versus unstimulated HC 
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LPMCs; *p<0.001 versus anti-CD3/CD28-stimulated HC LPMCs and 
versus all unstimulated LPMCs. Results are mean  SD. Lower panel. 
Production of IL-17 and IFN-γ by LPMCs, expressed as ratio between 
cytokine concentration after anti-CD3/CD28 stimulation and those in 
unstimulated conditions. Numbers are ratios.  
 
3.3 Analysis of Th17 and Th1/Th17 Cells 
 
To determine the percentage of mucosal T cells producing IL-17 and 
IFN-, we cultured LPMCs isolated from inflamed mucosa of 17 IBD 
patients (10 with CD and 7 with UC) and from normal mucosa of 9 
control subjects for 4h with PMA and ionomycin in the presence of 
monensin. As shown in Figure 7A, the percentage of CD3
+ 
LPMCs 
producing IL-17 was significantly (p<0.05) higher in CD patients (mean 
5.6  3.3%) and UC patients (mean 6.7  3.1%) in comparison to 
controls (mean 2.4  1.9%). Likewise, the percentage of CD3+ LPMCs 
producing IFN- was significantly higher (p<0.05) in CD patients (mean 
18.8  6.0%) and UC patients (mean 17.5  2.6%) in comparison to 
controls (mean 11.8  2.7%). Finally, the percentage of CD3+ LPMCs 
producing both IL-17 and IFN- was significantly (p<0.05) higher in CD 
patients (mean 1.9  1.4%) and UC patients (mean 2.6  1.6%) in 
comparison to controls (mean 0.7  0.4%). No significant difference was 
found between CD and UC in terms of production of IFN- alone, IL-17 
alone, and both IL-17 and IFN-. In Figure 7B, representative dot plots 
show the flow cytometric analysis of gated CD3
+
 LPMCs producing IL-
17 and IFN- in a control subject, a CD and a UC patient. A higher 
proportion of Th1/Th17 cells were observed in the CD3
+
CD161
+
 pool 
than in the CD3
+
CD161
-
 pool of LPMCs (Figure 7C). 
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Figure 7. A. Percentages of CD3
+
 LPMCs producing IF,N- only (Th1 
cells), IL-17 only (Th17 cells), or both (Th1/Th17 cells), assessed by flow 
cytometry after cytokine intracellular staining in 9 control subjects (HC), 
10 Crohn’s disease (CD) patients and 7 ulcerative colitis (UC) patients. 
Cells were analysed after 4-h stimulation with PMA and ionomycin and 
the Mann-Whitney U test has been used for statistical analysis. Results 
are mean  SD. *p<0.05 versus HC LPMCs. B. Flow cytometric analysis 
of PMA/ionomycin-stimulated LPMCs producing IL-17 and IFN- in 
gated CD3
+
 cells. Numbers within the dot plots represent the 
percentages of Th1 cells (lower-right quadrant), Th17 cells (upper-left 
quadrant), and Th1/Th17 cells (upper-right quadrant). The example is 
representative of experiments performed in 9 control subjects, 10 CD 
patients and 7 UC patients. C. Flow cytometric analysis of 
PMA/ionomycin-stimulated LPMCs producing IL-17 and IFN- in gated 
CD3
+
CD161
+
 and CD3
+
CD161
-
 cells. Numbers within the dot plots 
represent the percentages of Th1 cells (lower-right quadrant), Th17 cells 
(upper-left quadrant), and Th1/Th17 cells (upper-right quadrant). The 
example is representative of experiments performed in 6 control subjects, 
6 CD patients and 6 UC patients.  
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3.4 Control of IL-17 and IFN- Production by Pro-Inflammatory 
Cytokines 
 
Anti-CD3/CD28-stimulated LPMCs from 11 CD patients and 8 UC 
patients were cultured for 48h with IL-1 plus IL-6, IL-23 or IL-12. No 
effect was exerted by IL-1 plus IL-6, or IL-23 alone on the production 
of IL-17 and IFN- both in CD and UC patients (Table 5). 
 
Table 5. Levels of IL-17 and IFN- (pg/ml) in the supernatants of anti-
CD3/CD28-stimulated (CD3/CD28) LPMCs isolated from the inflamed 
colon of 11 Crohn’s disease (CD) patients and 8 ulcerative colitis (UC) 
patients, and cultured for 48h with 10 ng/ml IL-23 or 10 ng/ml IL-1 plus 
20 ng/ml IL-6. Data analysis has been performed using the Student’s t 
test. Results are mean (SE); *p<0.0001. 
  
  IL-17 
 
 
   IFN- 
  
CD 
 
 
UC 
 
CD 
 
UC 
 
Medium 
 
67 (37) 27 (11) 136 (63) 
 
99 
(43) 
 
CD3/CD28 
 
4701 (1183)* 
 
3552 
(1517)* 
 
2636 
(932)* 
2525 
(785)* 
CD3/CD28 
+ IL-23 
 
4771 (1234)* 
3277 
(1413)* 
2366 
(870)* 
2037 
(569)* 
CD3/CD28 
+ IL-1 + IL-6 
 
4736 (1220)* 
3586 
(1304)* 
2673 
(826)* 
2906 
(771)* 
 
In contrast, IL-12 significantly (p<0.05) decreased IL-17 production 
(from mean 6810 ± 2200 pg/ml to 2201 ± 1069 pg/ml; Figure 8A), while 
it significantly (p<0.005) up-regulated IFN- production (from mean 
6979 ± 419 pg/ml to 43341 ± 9086 pg/ml; Figure 8B). We then 
investigated the effect of IL-21 blockade on IL-17 production by 
culturing anti-CD3/CD28-stimulated LPMCs from 4 CD patients with an 
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anti-IL-21 blocking antibody (Figure 8C). The anti-IL-21 antibody 
significantly (p<0.05) decreased the IL-17 production in comparison to 
IgG-treated cells (from mean 700  291 pg/ml to 450  105 pg/ml). A 
significant (p<0.005) difference was also found in the production of IL-
17 between anti-CD3/CD28-stimulated cells cultured with IgG and 
unstimulated conditions (20  8 pg/ml). 
 
 
 
Figure 8. Levels (pg/ml) of IL-17 (A) and IFN- (B) in the supernatants 
of anti-CD3/CD28-stimulated LPMCs from the inflamed colon of 3 
ulcerative colitis (UC) patients and 3 Crohn’s disease (CD) patient, 
cultured for 48h with 5 ng/ml IL-12. Data were analyzed using the 
Student’s t test. Horizontal bars are mean. *p0.05 versus anti-
CD3/CD28-stimulated LPMCs; **p0.005 versus anti-CD3/CD28-
stimulated LPMCs. C. Levels (pg/ml) of IL-17 in the supernatants of 
LPMCs isolated from the inflamed colon of 4 CD patients stimulated 
with anti-CD3/CD28 antibodies and cultured for 48h with 20 g/ml anti-
IL-21 blocking antibody or its isotype control (mouse IgG). Results are 
mean ± SD. *p0.005 versus unstimulated LPMCs; **p0.05 versus 
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IgG-treated anti-CD3/CD28-stimulated LPMCs. 
 
3.5 Control of IL-17 and IFN- Production by TGF-1 
 
To investigate the role of TGF- in modulating IL-17 and IFN- 
production, we cultured anti-CD3/CD28-stimulated LPMCs from 4 CD 
patients and 3 UC patients with different concentrations of TGF-1. As 
shown in Figure 9, at different concentrations of TGF-1 (10, 1, 0.1 and 
0.01 ng/ml) the mean production of IL- 17 was respectively 67.7%, 
61.2%, 89.6% and 86.2% of that measured in the presence of medium 
only, while the mean production of IFN- was respectively 45.9%, 
41.6%, 69.9% and 92.1% of that measured in the presence of medium 
only. When we compared the inhibitory effects of TGF-1 on IFN- with 
those on IL-17, we found a significant (p<0.05) greater effect on IFN- 
production in comparison to IL-17 production at the TGF-1 
concentrations of 10 and 1 ng/ml. No significant difference was found at 
the TGF-1 concentrations of 0.1 and 0.01 ng/ml. 
 
 
 
Figure 9. Production of IL-17 and IFN- by anti-CD3/CD28-stimulated 
LPMCs isolated from the inflamed colon of 4 Crohn’s disease (CD) 
patients and 3 ulcerative colitis patients (UC), and cultured for 48h with 
different concentrations of TGF-1 (10, 1, 0.1 and 0.01 ng/ml). Cytokine 
levels in the supernatants of LPMCs cultured with TGF-1 are expressed 
as percentage of the cytokine production in the presence of medium only. 
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Data were analyzed using the Student’s t test. Horizontal bars are mean. 
 
 
4. Discussion 
 
The present study provides evidence that IL-17 production by gut 
biopsies grown ex vivo and LPMCs cultured in vitro is higher in IBD 
patients than in control subjects, and is associated with an increased 
percentage of Th17 and Th1/Th17 cells. Moreover, it seems that a 
differential regulation is played by pro- and anti-inflammatory cytokines 
on IL-17 and IFN- production by IBD LPMCs, the former down-
regulated by IL-12 but not TGF-, and the latter up-regulated by IL-12 
and down-regulated by TGF-. Finally, the results support a crucial role 
for IL-21 in controlling IL-17 production by CD LPMCs. 
I have first observed that IL-17 production from organ culture biopsies is 
increased in IBD patients in comparison to controls almost at the same 
levels of IFN-. In contrast with Kobayashi et al. [215], who found a 
higher in vivo mucosal production of IL-17 in UC than in CD, I did not 
observed any significant difference between these two disorders. When I 
measured the concentration of IL-17 in the supernatants of isolated 
LPMCs, I found a higher production of IL-17 and IFN- in IBD patients 
in comparison to controls, both in unstimulated and stimulated 
conditions. Again, no difference was found between CD and UC 
LPMCs. The fact that IL-17 production by organ culture biopsies was not 
increased in uninflamed areas of IBD patients further strengthens the key 
role of IL-17 in mediating inflammation. Of note, the absence of IL-17 
up-regulation in both unstimulated and stimulated LPMCs from inflamed 
areas of non-IBD patients suggests the specific contribution of IL-17 to 
the mucosal damage in CD and UC. 
IL-17 had been already investigated in the gut of IBD patients by 
immunohistochemistry which showed that IL-17 is markedly expressed 
by CD3
+
 and CD68
+
 cells in the inflamed mucosa [76]. Here I have used 
a dual parameter intracellular flow cytometry to spot IL-17 and IFN- 
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producing cells. Three cellular subsets have been identified, namely IFN-
-producing T cells (Th1), IL-17-producing T cells (Th17), and IL-
17/IFN- co-producing T cells (Th1/Th17). All were increased in CD and 
UC patients, without any difference between UC and CD. Interestingly, I 
have observed that the majority of Th1/Th17 cells expressed CD161, a 
well known marker of NK T cells recently identified on IL-17-producing 
memory T cells [166].
 
There is good evidence that IL-17 production is differentially regulated 
in mouse and human. In mice, IL-1β, IL-6 and TGF-β appear to be 
responsible for Th17 cell differentiation [155,221], while IL-23 is 
required for their expansion and/or maintenance [154]. In contrast, 
human studies showed that TGF-β, IL-1β and IL-6 are critical for the 
priming of Th17 responses [132,155,162]. More recent studies have 
shown that IL-21, IL-23, TGF-, and IL-1 plus IL-6 are able to induce 
IL-17 production from naïve human CD4
+
 T cells isolated from 
umbilical cord blood [164,165].
 
Hence, it seems that IL-1β and IL-6 
induce IL-17 secretion by central memory T cells, while TGF-β and IL-
21 are required to promote the differentiation of naïve CD4
+
 T cells into 
Th17 cells [163].
 
In my experience, neither IL-1β plus IL-6 nor IL-23 
alone were able to induce IL-17 and IFN- production by anti-
CD3/CD28-stimulated IBD LPMCs. The discrepancy between these and 
Yang’s [163] data might depend on the different source of cells used -
peripheral blood or inflamed mucosa- which could affect the effector-to-
memory T cell ratio in the cell sample. In contrast, IL-12 greatly 
enhanced IFN- production, while it reduced IL-17 secreted by anti-
CD3/CD28-stimulated IBD LPMCs. Given that it is known that IFN- in 
CD is driven by IL-12 and accessory cytokines such as IL-18 and IL-21, 
the notion that IL-12 suppresses IL-17 production is interesting because 
it suggests that perhaps a component of the rather weak efficacy of anti-
IL-12/IL-23 p40 antibody in active CD is that it allows Th17 
differentiation and a second effector function activated by the therapy 
itself. However, it must be also noted that IFN-, induced by IL-12, 
appears to play a role in limiting IL-17 production [222]. 
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Interestingly, TGF-, a cytokine known to have a pleiotropic function in 
controlling gut inflammation [223],
 
significantly reduced IFN- 
production by anti-CD3/CD28-stimulated IBD LPMCs, while the 
inhibitory effect was not significant on IL-17 production at the same 
concentrations. Although experiments have been performed in a small 
number of patients, this might shed light on the role of IL-17 in IBD as a 
key cytokine in sustaining chronic gut inflammation, which seems to be 
less regulated by immunomodulatory factors like TGF-. It has been 
previously shown that IFN- transcripts are not as well inhibited by 
active TGF-β in cells from CD patients as they are in cells from controls 
[224]. I confirmed this here in that TGF-β did not completely shut off 
IFN- production, only reducing it by about 50%. This is in keeping with 
a couple of studies which demonstrated that Th17 cells appear to be 
resistant to the suppressive effects of TGF-β-producing Tregs [149,225]. 
The lack of effect of TGF-β is due to the presence of Smad7, the 
intracellular inhibitor of TGF-β signalling in cells from IBD patients 
[226]. Critically however to understand why TGF-β only barely inhibited 
IL-17 production in IBD is the fact that TGF-β appears to be important 
for Th17 cell generation. It has been proposed by Zhou et al. [161] that T 
cells receiving a TGF-β signal can develop into either the T regulatory 
cell or Th17 lineage. Foxp3 induction may restrain the differentiation of 
inflammatory Th17 cells in response to TGF-β in the absence of other 
pro-inflammatory cytokines by inhibiting RORγt activity. In the presence 
of pro-inflammatory cytokines, the suppression of Foxp3 expression and 
inhibitory function, together with the concurrent up-regulation or 
stabilization of RORγt expression, may favour the development into 
Th17 lineage. Thus, a fine balance between RORγt and Foxp3 might be 
critical for immune homeostasis in the gut. 
IL-21 is another pro-inflammatory cytokine overproduced in the 
inflamed intestine of patients with CD. CD4+ T cells infiltrating CD 
mucosa are the main source of IL-21. In CD LPMC cultures, IL-21 
blockade reduces the expression of p-Stat4 and T-bet and the production 
of IFN- [191]. In keeping with the findings of Fina et al. [78], these 
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results show that IL-21 blockade significantly reduces IL-17 secretion by 
CD LPMCs. 
In conclusion, this study demonstrates the importance of Th17 and 
Th1/Th17 cells in the pathogenesis of IBD, and further clarifies which 
stimuli can modulate and maintain IL-17 production. The differential 
effect of TGF- on IL-17 and IFN- production suggests that IL-17 plays 
a crucial role in sustaining chronic inflammation. These findings also 
support a role for IL-21, IL-12 but not TGF- in modulating IL-17 
production in IBD.  
Treatment strategies in IBD are largely focused on the suppression or 
modulation of the excessive immune response in the gut. However, due 
to the involvement of different cytokines and individual variability, the 
main challenge is to identify inflammatory pathways and develop 
disease-specific therapies that can be tailored for each patient [74]. The 
multiple faces of the pathogenesis of IBD will lead soon to develop 
disease-specific therapies and hopefully to recognize which patients will 
better respond to a particular therapy. In this context, this study suggests 
that the abundant IL-17 in inflamed mucosa may also help explain the 
relative lack of efficacy of anti-IFN- antibodies in clinical trials, 
suggesting the existence of a Th1/Th17 population which may represent 
an intermediate phenotype between Th1 and Th17 cells. 
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